Base de données de lignes directrices sur le cancer

Vous pouvez consulter des lignes directrices de qualité sur le cancer à partir d’une seule source canadienne.

Voici une liste de 450 lignes directrices sous le(s) thème(s)"Continuum of care". Les plus récentes sont en premier.

Older Adult Oncology, Version 1.2019

Year: 2019
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for older patients with cancer. The guideline provides recommendations for comprehensive geriatric assessments, as well as treatment modalities such as surgery, radiation therapy (RT), chemotherapy, and targeted therapy. Disease-specific issues are also addressed for breast cancer, central nervous system cancers, gastrointestinal cancers, genitourinary cancers, gynecological cancers, head and neck cancers, lung cancers, melanoma, and hematologic malignancies.

Neuroendocrine and Adrenal Tumours, Version 4.2018

Year: 2019
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

Endoscopic Surveillance After Surgical or Endoscopic Resection for Colorectal Cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline

Year: 2019
AGREE II score: Disponible
Developer organization: European Society of Gastrointestinal Endoscopy (ESGE)
This is a clinical practice guideline for patients who have been operated on for sporadic colorectal cancer (CRC) and for those in whom a low risk T1 CRC has been completely removed at endoscopy. The guideline discusses the endoscopic surveillance of these patients, and provides recommendations on the appropriate timing of endoscopy (i.e. in specific intervals following surgery), and the age at which to halt the use of surveillance endoscopy. Outcomes of interest include overall survival, CRC-specific survival, relapse-free survival, and adverse effects.

Evidenced-Based Guideline for Colorectal Cancer

Year: 2019
AGREE II score: Disponible
Developer organization: German Guideline Program in Oncology
This is a clinical practice guideline for physicians who work on the prevention and treatment of colorectal cancer in the ambulatory and inpatient sector. The guideline provides recommendations for prevention, screening in asymptomatic populations as well as high risk populations, the role of endoscopy in the diagnosis of polyps and colorectal cancer, pre-operative diagnostics and surgery, adjuvant and neoadjuvant therapy, management of patients with metastases, palliative care and follow-up care.

The Management of Primary Mediastinal B-cell Lymphoma: A British Society for Haematology Good Practice Paper

Year: 2019
AGREE II score: Disponible
Developer organization: British Society for Haematology
This is a clinical practice guideline for patients with primary mediastinal B-cell lymphoma. The guideline examines the staging, therapy, response assessment, relapse or refractory disease, and follow-up of these patients. The effect of chemotherapy on fertility and pregnancy is discussed, as well as thrombotic complications of superior vena cava obstruction (SVCO).

European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas

Year: 2018
AGREE II score: Disponible
Developer organization: European Society of Endocrinology
This is a clinical practice guideline for patients with aggressive pituitary tumours and carcinomas, which provides recommendations on diagnosis, treatment, and follow-up. Treatment options such as surgery, radiotherapy, and temozolomide are examined. Further guidance on dosing regimens, adverse effects, discontinuation, and combination chemotherapies is provided for temozolomide. Recurrence, non-responders, and systemic metastasis are also discussed.

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline

Year: 2018
AGREE II score: Disponible
Developer organization: Endocrine Society
This is a clinical practice guideline for survivors of childhood cancer. The guideline provides recommendations for the endocrine treatment of hypothalamic-pituitary and growth disorders in these patients. Specific conditions discussed include impaired linear growth, growth hormone deficiency, central precocious puberty, hypogonadotropic hypogonadism, and thyroid-stimulating hormone deficiency.

Guidelines for the Diagnosis and Management of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Year: 2018
AGREE II score: Disponible
Developer organization: British Society for Haematology
This is a clinical practice guideline for patients who have or are suspected of having primary central nervous system diffuse large B-cell lymphoma (PCNSL) located in the brain, spinal cord, cranial nerves, eyes or meninges. Specific topics discussed include diagnosis and imaging, treatment of primary CNS lymphoma, remission induction, consolidation treatment, follow-up, relapsed and refractory PCNSL, and neuropsychological assessments.

Vulvar Cancer (Squamous Cell Carcinoma), Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

Occult Primary (Cancer of Unknown Primary [CUP]), Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with epithelial occult primary cancer. The guideline provides recommendations for the evaluation, workup, management, and follow-up of two pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma, or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Management options considered include, chemotherapy, radiation therapy, locoregional therapeutic options, and specialized approaches, as well as supportive care and management of psychosocial distress.

Merkel Cell Carcinoma, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.

Myeloproliferative Neoplasms, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma. The guideline examines the diagnosis, workup, primary treatment regimens, assessment of response to primary treatment, and follow-up after primary treatment. Regimens not toxic to stem cells and regimens with potential or unknown toxicity to stem cells are considered. Treatment of Immunoglobulin M (IgM) related peripheral neuropathy, maintenance therapy, and therapy for previously treated Waldenström's macroglobulinemia are also discussed.

Myeloid Growth Factors, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with solid tumours and non-myeloid malignancies who are receiving myelosuppressive chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) in these patients as a method for reducing the incidence of neutropenia. Topics of interest include the benefits and risks of MGFs, as well as their use in prophylactic, therapeutic, and post-transplant settings.

Thyroid Carcinoma, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with diagnosed or suspected thyroid carcinoma. The guideline discusses the initial workup, diagnosis, staging, treatment, and follow up of patients with differentiated, papillary, follicular, medullary, and anaplastic thyroid carcinoma, as well as Hürthle cell carcinoma. Surgery, radiation therapy, and systemic therapy are discussed as treatment options.

Thymomas and Thymic Carcinomas, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with thymomas and thymic carcinomas. The guideline examines the diagnosis, staging, and treatment these mediastinal tumours. Surgical resection and radiation therapy are discussed as treatment options.

Colon Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

Lymphoma

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients who have been diagnosed with or are suspected of having lymphoma. The guideline discusses Hodgkin lymphoma, as well as the most common non-Hodgkin lymphomas (T-cell and B-cell). Recommendations are provided on diagnosis, staging, treatment, management, and follow up care.

Penile Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Pancreatic Adenocarcinoma, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

Kidney Cancer, Version 4.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.

Head and Neck Cancers, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with head and neck cancers. The guideline examines workup and staging, treatment, and follow-up for various head and neck cancers including cancer of the lip, oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx, as well as paranasal tumours, very advanced head and neck cancers, occult primary cancer, salivary gland tumours, and mucosal melanoma of the head and neck. Nutrition, supportive care, comorbidities, quality of life, and dental evaluation and management are also discussed.

Rectal Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 5.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.

Bladder Cancer, Version 4.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

Anal Carcinoma, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline is for the management of squamous cell anal carcinoma. The guideline provides recommendations on staging, treatment, and follow-up. The effectiveness of treatment options such as surgery, chemotherapy, and radiation therapy are compared. Guidance is also provided on dosing regimens, treatment of recurrence, and surveillance following treatment of recurrence.

Acute Myeloid Leukemia, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratifications based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

ACR Appropriateness Criteria Post-Treatment Follow-Up Prostate Cancer

Year: 2018
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for patients who have received treatment for prostate cancer. The guideline examines the various imaging modalities that can be effectively used for the follow-up of these patients. Variations of imaging modalities such as transrectal ultrasound (TRUS), magnetic resonance imaging (MRI), and computed tomography (CT) are discussed, and the appropriateness of different techniques is examined for different clinical situations.

Pancreatic Adenocarcinoma, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with pancreatic adenocarcinoma. The guideline examines risk factors and genetic predisposition, pancreatic cancer screening, diagnosis and staging, systemic therapy approaches, radiation and chemoradiation approaches, surveillance of patients with resected disease, as well as palliative and supportive care. Management of metastatic disease, locally advanced disease, resectable and borderline resectable disease, and recurrent disease after resection is also considered.

Kidney Cancer, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline specifically examines the initial evaluation, staging, diagnosis, clinical management options, and follow-up of patients with clear cell carcinoma and non-clear cell carcinoma. Pharmacologic agents discussed include pazopanib, sunitinib, and nivolumab.

Chronic Myeloid Leukemia, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic myeloid leukemia (CML). The guideline discusses diagnosis and workup, staging, and management options for these patients, and includes specific considerations for children with CML. The guideline separates treatment options based on characteristics such as genetic profile, and phase (i.e. chronic phase, accelerated phase, and blast phase). Topics discussed include toxicities and response milestones for different treatment options.

Bone Cancer, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bone cancer. The guideline focuses on chordoma, chondrosarcoma, Ewing sarcoma, osteosarcoma, and provides recommendations for treating giant cell tumour of the bone (GCTB). Workup, treatment, surveillance, and relapsed disease are discussed for each of the types of bone cancer mentioned. Staging, high-grade undifferentiated pleomorphic sarcoma of bone, and immunotherapy for bone cancer are also considered.

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Year: 2018
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This clinical practice guideline is a focused update of the American Society of Clinical Oncology's 2016 adaptation of Cancer Care Ontario's guideline on the selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for breast cancer. New recommendations are provided on the addition of adjuvant capecitabine after completion of standard preoperative anthracycline- and taxane-based combination chemotherapy, the addition of 1 year of adjuvant pertuzumab to combination chemotherapy and trastuzumab, and the use of neratinib as extended adjuvant therapy in patients with early-stage human epidermal growth factor receptor 2 (HER2)-amplified or HER2-overexpressed breast cancer.

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Year: 2018
AGREE II score: Disponible
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with non-small cell lung cancer (NSCLC). The guideline provides recommendations on the use of immunotherapy as treatment for these patients, using the immune checkpoint inhibitors pembrolizumab, nivolumab and atezolizumab. Specific topics discussed include appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing.

Testicular Cancer, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

Provincial Esophageal Cancer and Gastro-Esophageal Junction Cancer Treatment Guidelines

Year: 2018
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for adult patients with esophageal cancer or cancer of the gastro-esophageal junction. The guideline provides recommendations on assessment, systemic therapy, surgical approaches, and post-curative therapy follow-up of these patients. The discussion of treatment is stratified by stage, performance status, and disease type. Chemotherapy regimens are also considered.

Myeloid Growth Factors, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with solid tumours and non-myeloid malignancies who are receiving myelosuppressive chemotherapy. The guideline examines the use of myeloid growth factors (MGFs) in these patients as a method for reducing the incidence of neutropenia. Topics of interest include the benefits and risks of MGFs, as well as their use in prophylactic, therapeutic, and post-transplant settings.

Cancer- and Chemotherapy-Induced Anemia, Version 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults and children with cancer-induced anemia (CIA). The guideline discusses the etiology of CIA, and examines the screening, evaluation, and treatment methods for reducing CIA in affected patients. Red blood cell transfusion, erythropoietic therapy, and iron monitoring and supplementation are discussed as treatment options.

Thyroid Carcinoma, Version 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with diagnosed or suspected thyroid carcinoma. The guideline discusses the initial workup, diagnosis, staging, treatment, and follow up of patients with differentiated, papillary, follicular, medullary, and anaplastic thyroid carcinoma, as well as Hurthle cell carcinoma. Surgery, radiation therapy, and systemic therapy are discussed as treatment options.

Penile Cancer, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of squamous cell carcinoma (SCC) of the penis. The guideline examines the diagnosis, treatment, and follow-up for patients with this form of cancer. Outcomes of interest include optimizing therapeutic efficacy and minimizing treatment-related morbidity.

Non-Small Cell Lung Cancer, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.

Primary Cutaneous Lymphomas, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Multiple Myeloma, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

Hepatobiliary Cancers, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

Colon Cancer, Version 4.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of colon cancer. Recommendations are made for diagnosis, pathologic staging, surgical management, perioperative treatment, surveillance, and management of recurrence. Principles for the management of metastatic disease are also provided.

AIDS-Related Kaposi Sarcoma, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

Acute Myeloid Leukemia, Version 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with acute myeloid leukemia (AML), including those with acute promyelocytic leukemia (APL). The guideline examines the initial evaluation of AML, risk stratification based on cytogenetics and molecular markers, management options, as well as supportive care. Management strategies are separated based on whether patients are above or below sixty years of age.

Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2018
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for men with metastatic non-castrate prostate cancer being considered for treatment with androgen-deprivation therapy (ADT). The guideline examines the addition of docetaxel or abiraterone to ADT, and the resulting effects on overall survival (OS), progression-free survival (PFS), failure-free survival (FFS), prostate-specific antigen (PSA) response, overall response rate, and quality of life (QOL).

Oesophago-Gastric Cancer: Assessment and Management in Adults

Year: 2018
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults with newly-diagnosed or recurrent oesophago-gastric cancer. The guideline discusses clinical assessment, radical and palliative treatment, follow-up, nutritional support, and service organization. The primary outcomes of interest are increases in quality of life and survival.

Canadian Urological Association Guideline for Follow-up of Patients After Treatment of Non-Metastatic Renal Cell Carcinoma

Year: 2018
AGREE II score: Unavailable
Developer organization: Canadian Urological Association
This is a clinical practice guideline for patients who have been treated for non-metastatic renal cell carcinoma (RCC). The guideline examines the follow-up of these patients, and recommendations are provided for surveillance, clinical assessment, blood biochemistry tests, and imaging techniques.

Guidelines for the Management of Chemotherapy Induced Nausea and Vomiting in Children With Cancer

Year: 2018
AGREE II score: Unavailable
Developer organization: Atlantic Provinces Pediatric Hematology Oncology Network
This clinical practice guideline discusses the prevention and management of chemotherapy induced nausea and vomiting (CINV) in pediatric cancer patients. Acute, delayed, anticipatory, breakthrough and refractory CINV are discussed. Recommendations are provided on assessment as well as pharmacological and non-pharmacological interventions. Antiemetic dosing recommendations are also provided.

Brain Tumours (Primary) and Brain Metastases in Adults

Year: 2018
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for patients aged 16 or older who have primary brain tumours or brain metastases. Specifically, the guideline examines the diagnoses and management of radiologically identified glioma, meningioma, and brain metastases. Follow-up care after treatment and supportive care are also discussed, and additional recommendations are provided on the referral of adults with primary brain tumours or brain metastases for neurological rehabilitation assessment.

Guidelines for Enhanced Recovery After Lung Surgery: Recommendations of the Enhanced Recovery After Surgery (ERAS) Society and the European Society of Thoracic Surgeons (ESTS)

Year: 2018
AGREE II score: Disponible
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline for the optimal preoperative management of patients undergoing thoracic surgery, and primarily, lung resection. Topics covered in the guideline include preoperative counselling, nutritional screening, smoking cessation, prehabilitation for high-risk patients, avoidance of fasting, carbohydrate loading, avoidance of preoperative sedatives, venous thromboembolism prophylaxis, prevention of hypothermia, short-acting anesthetics to facilitate early emergence, regional anesthesia, nausea and vomiting control, opioid-sparing analgesia, euvolemic fluid management, minimally invasive surgery, early chest drain removal, avoidance of urinary catheters and early mobilization after surgery.

Hairy Cell Leukemia, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

Small Cell Lung Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.

Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adult patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Recommendations are provided for screening, staging, diagnosis, treatment, and follow-up. Treatment options discussed include debulking surgery, chemotherapy, and radiation therapy. Management of drug reactions is also discussed.

Neuroendocrine and Adrenal Tumors, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with neuroendocrine or adrenal tumours. The guideline discusses the diagnosis, staging, treatment, and follow-up of patients with sporadic neuroendocrine tumours, originating from organs such as the lungs, thymus, and gastrointestinal (GI) tract. The guideline also examines the role of the genetic syndrome, multiple endocrine neoplasia (MEN), in developing parathyroid, pituitary, and pancreatic tumours.

Cancer in People Living with HIV, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

Adolescent and Young Adult (AYA) Oncology, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

Systemic Mastocytosis, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with systemic mastocytosis (SM). The guideline provides recommendations on the diagnostic criteria for variants of SM, as well as for treatment and follow-up. Specific variants discussed include indolent SM, smoldering SM, aggressive SM, and SM with an associated hematological neoplasm.

Myelodysplastic Syndromes, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

Rectal Cancer, Version 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of rectal cancer. The guideline provides recommendations regarding diagnosis, pathologic staging, surgical management, perioperative treatment, management of recurrent and metastatic disease, and patient surveillance. Outcomes of interest include safety and efficacy of treatment, adverse outcomes, and overall survival.

Breast Cancer, Version 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with breast cancer. The guideline examines the staging, pathology assessment, and treatment approach for these patients. Pure non-invasive carcinomas (stage 0), stage 1, 2A, 2B or 3A (T3, N1, M0) invasive breast cancer, stage 3 invasive breast cancer, and stage 4 metastatic or recurrent breast cancer are discussed. Special situations including Paget's disease, phyllodes tumours of the breast, breast cancer during pregnancy, inflammatory breast cancer, and axillary breast cancer are also considered.

Chronic Lymphocytic Leukemia

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines the diagnostic and staging criteria, treatment strategies, and follow-up and supportive care practices for these patients. First and second line treatment options are discussed for newly diagnosed, relapsed, and refractory disease.

Local Prostate Cancer

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult men with a suspicion or recent diagnosis of localized prostate cancer. The guideline examines staging, treatment options, and follow-up for these patients. Management is discussed for low, intermediate, and high-risk disease. Treatment options considered include variations of radical prostatectomy, brachytherapy, external beam radiotherapy, cryosurgery, and active surveillance.

Advanced / Metastatic Prostate Cancer

Year: 2018
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients who have been diagnosed with or are suspected of having advanced/metastatic prostate cancer. The guideline provides guidance on the staging, treatment, and follow up procedures for these patients. Topics of interest include radiotherapy techniques, the use of bone scans to assist in staging, and follow-up using active surveillance within a cancer clinic.

Cancer-Related Fatigue, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults and children experiencing cancer-related fatigue (CRF). The guideline discusses screening for CRF, as well as evaluation approaches using focused history, assessment of treatable contributing factors, and patient clinical status. General strategies for managing CRF are discussed, and the guideline examines pharmacological and non-pharmacological treatments for patients based on their placement within the care continuum (i.e. active treatment, post-treatment, and end-of-life).

Soft Tissue Sarcoma, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.

T-Cell Lymphomas, Version 4.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with T-cell lymphoma. The guideline examines the diagnostic workup, staging, treatment, follow-up, and supportive care for the most common subtypes of T-cell lymphoma. These subtypes include peripheral T-cell lymphomas (PTCLs), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), mycosis fungoides (MF) and Sézary syndrome (SS), primary cutaneous CD30+ T-cell lymphoproliferative disorders, T-cell large granular lymphocytic leukemia (TGLL), adult T-cell leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (TPLL), and extranodal NK/T-cell lymphomas (ENKL), nasal type.

B-Cell Lymphomas, Version 4.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, treatment and surveillance of B-cell lymphoma (BCL) in pediatric and adult patients. The guideline focuses on the most common B-cell lymphomas: follicular lymphoma (FL), marginal zone lymphomas (MZL), nodal MZL, splenic MZL, gastric MALT lymphoma, mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), AIDS-related B-cell lymphoma, post-transplant lymphoproliferative disorders, and Castleman's disease. Additional consideration is paid to the classification systems used in NHL, the role of PET scans in assessment and staging, principles of radiation therapy, and supportive care considerations.

Myelodysplastic Syndromes, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myelodysplastic syndromes (MDS). The guideline discusses diagnostic classification, evaluation, prognostic stratification, therapeutic options, and recommended treatment approaches for MDS. There is a particular focus on supportive care, and the guideline also provides recommendations for the management of thrombocytopenia and iron overload, the treatment of related anemia, the use of low-intensity therapy (i.e. hypomethylating agents or biologic response modifiers and immunosuppressive therapy), and high-intensity therapy.

Multiple Myeloma, Version 4.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with multiple myeloma. The guideline examines the primary therapy and surveillance/follow-up tests for both solitary plasmacytoma and smoldering (asymptomatic) myeloma, and the primary therapy and monitoring for active (symptomatic) myeloma. Stem cell transplants (SCT), including autologous SCT, tandem SCT, and allogeneic SCT, as well as follow-up after stem cell transplants, are also discussed. In addition, the guideline considers diagnostic tests, response criteria, maintenance therapy, treatment of progressive or relapsed myeloma, and supportive care treatment.

Hepatobiliary Cancers, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for hepatobiliary cancers. The guideline examines the clinical management of patients with hepatocellular carcinoma (HCC), gallbladder cancer, as well as intrahepatic and extrahepatic cholangiocarcinoma. Risk factors, diagnosis, staging and prognosis, and treatment are discussed for the different conditions.

Esophageal and Esophagogastric Junction Cancers, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with esophageal or esophagogastric junction cancer. The guideline examines the initial workup, histological staging, primary treatment, and follow-up of both squamous cell carcinoma and adenocarcinoma. Treatment modalities discussed include surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies.

Breast Cancer, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with breast cancer. The guideline examines staging, pathology assessment, and treatment approaches for pure noninvasive carcinomas, stage I, IIA, IIB, IIIA, or III invasive breast cancer, and stage IV metastatic or recurrent breast cancer. Special situations considered include Paget's disease, phyllodes tumours of the breast, breast cancer during pregnancy, inflammatory breast cancer, and axillary breast cancer.

ACR Appropriateness Criteria Staging and Follow-Up of Ovarian Cancer

Year: 2018
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for women with epithelial ovarian cancers, specifically focusing on patients with type-2 ovarian cancers. The guideline examines diagnostic imaging methods, used for both staging and evaluating potential recurrence. Imaging modalities discussed include x-ray, magnetic resonance imaging (MRI), fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and computed tomography (CT).

T-Cell Lymphomas, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with T-cell lymphoma. The guideline examines the diagnostic workup, staging, treatment, follow-up, and supportive care for the most common subtypes of T-cell lymphoma. These subtypes include peripheral T-cell lymphomas (PTCLs), breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), mycosis fungoides (MF) and Sezary syndrome (SS), primary cutaneous CD30+ T-cell lymphoproliferative disorders, T-cell large granular lymphocytic leukemia (TGLL), adult T-cell leukemia/lymphoma (ATLL), T-cell prolymphocytic leukemia (TPLL), and extranodal NK/T-cell lymphomas (ENKL), nasal type.

Early and Locally Advanced Breast Cancer: Diagnosis and Management

Year: 2018
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for the diagnosis and management of early and locally advanced breast cancer. The guideline provides recommendations on referral, diagnosis, preoperative assessment, genetic testing, surgical procedures, breast reconstruction, psychological support, and adjuvant therapies such as endocrine therapy and bisphosphonate therapy.

Guidelines for the Investigation and Management of Transient Leukaemia of Down Syndrome

Year: 2018
AGREE II score: Disponible
Developer organization: British Society for Haematology
This is a clinical practice guideline for children with suspected or confirmed transient leukemia of Down syndrome (TL-DS). The guideline examines the clinical features and diagnosis of TL-DS, outcomes, risk factors for early death, and treatment of TL-DS, as well as monitoring for resolution of TL-DS and development of myeloid leukemia of Down syndrome (MI-DS). Fetal TL-DS, silent TL-DS and screening for mutations in the hematopoietic transcription factor gene GATA1 are also discussed.

Older Adult Oncology, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for older patients with cancer. The guideline provides recommendations for comprehensive geriatric assessments, as well as treatment modalities such as surgery, radiation therapy (RT), chemotherapy, and targeted therapy. Disease-specific issues are also addressed for breast cancer, central nervous system cancers, gastrointestinal cancers, genitourinary cancers, gynecological cancers, head and neck cancers, lung cancers, melanoma, and hematologic malignancies.

A Guideline for the Diagnosis and Management of Polycythemia Vera

Year: 2018
AGREE II score: Disponible
Developer organization: British Society for Haematology
This is a clinical practice guideline for patients with polycythemia vera (PV). The guideline provides recommendations on diagnosis, risk stratification and management of PV. Specific topics discussed include the initial assessment, stage 1 investigations, considerations based on erythropoietin (EPO) levels, gene sequencing for congenital erythrocytosis, and cytoreductive therapy.

Soft Tissue Sarcoma, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the management of soft tissue sarcoma (STS) in adult patients. The guideline pertains to the following five subtypes of STS: (1) STS of extremity, superficial/trunk, or head and neck, (2) retroperitoneal or intra-abdominal STS, (3) gastrointestinal stromal tumours (GISTs), (4) desmoid tumours, and (5) rhabdomyosarcoma (RMS). The guideline provides recommendations for diagnosis, staging, treatment, palliative care, and surveillance. Surgery, chemotherapy, and radiotherapy are all examined as treatment options.

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with chronic lymphocytic leukemia, or small lymphocytic lymphoma. The guideline examines the diagnosis, staging, treatment, and follow-up of these patients. Prognosis and treatment algorithms are presented based on patient characteristics such as age, and genetic profile.

Cervical Cancer, Version 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

Bladder Cancer, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with bladder cancer. Non-muscle-invasive urothelial bladder cancer, muscle-invasive urothelial bladder cancer, metastatic (Stage IVB) urothelial bladder cancer, non-urothelial carcinomas of the bladder, upper tract urothelial carcinoma (UTUC), urothelial carcinomas of the prostate, and primary carcinomas of the urethra are all specifically discussed. The guideline provides algorithms for diagnosis, staging, treatment, and follow-up.

Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Year: 2018
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This clinical practice guideline is a focused update of the American Society of Clinical Oncology's 2016 guideline on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. The guideline specifically examines whether extended adjuvant therapy, including the use of aromatase inhibitors (AIs), improves clinically meaningful outcomes (e.g. disease-free survival, overall survival, quality of life, toxicity) after 5 years of sequential endocrine therapy in postmenopausal women with hormone receptor-positive early breast cancer.

Small Cell Lung Cancer, Version 1.2019

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.

Cancer in People Living With HIV, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients living with HIV (PLWH) who are diagnosed with cancer. The guideline focuses primarily on PLWH who develop non-small cell lung cancer (NSCLC), anal cancer, Hodgkin lymphoma, or cervical cancer. General advice is also provided regarding HIV management during cancer therapy, in addition to topics such as drug-drug interactions (DDI) between antiretroviral treatments and cancer therapies, initial workup, radiation therapy, surgical management, and supportive care.

Adult Cancer Pain, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with any type of cancer. The guideline focuses on the screening, assessment, and treatment of cancer-related pain. Specific topics discussed include universal pain screening, management of pain in both opioid-naïve and opioid-tolerant patients, management of opioid-induced adverse effects, procedure-related pain and anxiety, management strategies for specific cancer pain syndromes, adjuvant analgesics for neuropathic pain, psychosocial support, and education for both patients and caregivers.

Testicular Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines the clinical presentation, workup, primary treatment, and pathologic diagnoses of these patients. Separate recommendations are provided for different stages of pure seminomas and nonseminomas, and the guideline also discusses second-line and subsequent therapies for metastatic GCTs.

Non-Small Cell Lung Cancer, Version 5.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with non-small cell lung cancer. The guideline examines the risk factors, classification factors, diagnostic evaluation, pathologic evaluation, staging, predictive and prognostic biomarkers, treatment, and surveillance of lung cancer. Treatment approaches considered include surgery, radiation therapy, and combined modality therapy. The discussion on initial therapy is stratified by disease stage.

Hodgkin Lymphoma Version, 3.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The guideline discusses the clinical management of patients with CHL and NLPHL, focusing on patients who do not have serious intercurrent disease. Treatment options examined include chemotherapy, high dose therapy and autologous stem cell rescue (HDT/ASCR), and involved site radiation therapy (ISRT).

Gastric Cancer, Version 2.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults and children with gastric cancer. The guideline examines the pathology, initial workup, staging, treatment, follow-up, and supportive care of these patients. Treatment options discussed include lymph node dissection, laparoscopic resection, endoscopy, radiation therapy, combined modality therapy, chemotherapy (preoperative, perioperative, and postoperative), and targeted therapies.

Acute Lymphoblastic Leukemia, Version 1.2018

Year: 2018
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adolescent, young adult (AYA), and adult patients with acute lymphoblastic leukemia (ALL). The guideline reviews the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers, and provides recommendations on risk assessment and stratification for risk-adapted therapy, as well as treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL. The guideline also provides recommendations for supportive care.

Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma

Year: 2017
AGREE II score: Unavailable
Developer organization: International Myeloma Foundation
This is a clinical practice guideline for the management of venous thromboembolism (VTE) and cardiovascular disease (CVD) in patients with multiple myeloma. The guideline provides recommendations on assessment, diagnosis, prevention, treatment, and follow-up for VTE and CVD. Risk factors and risk stratification for VTE and CVD are discussed. The guideline also highlights multiple myeloma treatments with side-effects related to VTE and CVD.

EANO–ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Patients with Leptomeningeal Metastasis from Solid Tumours

Year: 2017
AGREE II score: Disponible
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients with leptomeningeal metastases from solid tumours. The guideline discusses the diagnosis, treatment, and follow-up of these patients, and a treatment algorithm is presented based on life expectancy. Treatment options examined include systemic pharmacotherapy, intra-cerebrospinal fluid pharmacotherapy, focal radiotherapy (RT), and whole brain radiotherapy (WBRT).

EAU Guidelines on Renal Cell Carcinoma

Year: 2017
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for adult patients with renal cell carcinoma (RCC). The guideline examines the staging, diagnosis, prognosis, treatment, and follow-up of these patients. Management recommendations are provided for treating localized RCC, locally advanced RCC, advanced/metastatic RCC, and recurrent RCC. The epidemiology, etiology, and pathology of RCC are also discussed.

EAU Guidelines on Urothelial Carcinoma of the Upper Urinary Tract

Year: 2017
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of urothelial carcinoma of the upper urinary tract (UTUC). The guideline provides recommendations on diagnosis, staging, treatment, and follow-up. Prognostic factors, predictors of survival and recurrence, as well as risk stratification are also discussed. Outcomes of interest include diagnostic accuracy, overall survival, recurrence rates, and adverse effects.

Guidelines for the Use of Imaging in the Management of Patients With Myeloma

Year: 2017
AGREE II score: Disponible
Developer organization: British Society for Haematology
This is a clinical practice guideline for adults with myeloma. The guideline examines the use and technical application of the latest imaging modalities at diagnosis and in the follow-up of patients with myeloma and plasmacytoma. Plain X-rays, whole body low-dose computed tomography (WBLDCT), and whole body magnetic resonance imaging (WB-MRI) are imaging techniques that are focused on.

Provincial Differentiated Thyroid Cancer (DTC) Treatment Guidelines

Year: 2017
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for patients with thyroid cancer. The guideline examines the diagnosis, treatment, management, and follow-up of these patients. Topics of interest include a shift towards a standardized ultrasound/cytologic concordance system to guide investigation and management of thyroid nodules, acceptance of thyroid lobectomy as an option for many low risk thyroid cancers, acceptance of either no or lower dose radio-iodine treatment for many low risk thyroid cancers, and dynamic risk stratified follow-up for thyroid cancer.

Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion

Year: 2017
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a provisional clinical opinion (PCO) for chemotherapy-naive men with castration-resistant prostate cancer (CRPC). This PCO examines second-line hormonal therapy and provides recommendations on staging, treatment, follow-up, and palliative care for men with CRPC. Outcomes of interest include overall survival, adverse events, quality of life, and treatment efficacy (defined as response in prostate-specific antigen values).

Influenza Immunization for Adult and Pediatric Patients Undergoing Cancer Treatment

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline discussing influenza immunization for adult and pediatric cancer patients. The guideline provides guidance on the timing of influenza immunization in relation to severity of immunosuppression and chemotherapy schedules, number of administrations, types of influenza vaccines, and contraindications and precautions for immunization. Recommendations for the immunization of family members and hospital or clinic staff are also provided.

Vulvar Cancer (Squamous Cell Carcinoma), Version 1.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with vulvar cancer, and particularly those with squamous cell carcinoma (SCC) of the vulva. The guideline examines diagnosis and workup, as well as primary treatment, adjuvant radiotherapy and chemotherapy, and surveillance of these patients. Treatment options are discussed for early-stage disease, locally advanced disease, and metastases beyond the pelvis.

Occult Primary (Cancer Of Unknown Primary [CUP]), Version 1.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with epithelial occult primary cancer. The guideline provides recommendations for the evaluation, workup, management, and follow-up of two pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma, or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Management options considered include, chemotherapy, radiation therapy, locoregional therapeutic options, and specialized approaches, as well as supportive care and management of psychosocial distress.

Myeloproliferative Neoplasms, Version 2.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with myeloproliferative neoplasms. The guideline specifically examines the diagnosis, risk-stratification, treatment, and supportive care for patients with polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Risk-stratified treatment algorithms are provided for each disorder.

Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 1.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma. The guideline examines the diagnosis, workup, primary treatment regimens, assessment of response to primary treatment, and follow-up after primary treatment. Regimens not toxic to stem cells and regimens with potential or unknown toxicity to stem cells are considered. Treatment of Immunoglobulin M (IgM) related peripheral neuropathy, maintenance therapy, and therapy for previously treated Waldenstrom's macroglobulinemia are also discussed.

Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This clinical practice guideline is an endorsement of the American Thyroid Association's 2015 guideline titled Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. The guideline provides recommendations on management of patients thyroid nodules and differentiated thyroid cancers. Topics include evaluation of thyroid nodules to determine the presence of malignancy, and management of differentiated thyroid cancer including surgery, radioactive iodine (RAI) therapy, hormonal therapy, external beam radiation therapy (EBRT), and systemic treatment.

Follow-up After Primary Therapy for Endometrial Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations on the follow-up of patients with endometrial cancer who are clinically disease free after receiving primary treatment. The guideline reviews symptomatic signs of possible recurrence. Recommendations are provided on follow-up intervals and diagnostic interventions, stratified by risk of recurrence.

Indications for Use of Breast Magnetic Resonance Imaging (MRI)

Year: 2017
AGREE II score: Unavailable
Developer organization: Eastern Health
This is a clinical practice guideline for the appropriate use of breast magnetic resonance imaging (MRI). The guideline examines indications for breast MRI use, such as for the screening of high risk individuals, for problem solving when mammographic, sonographic or clinical findings are suspicious but inconclusive, for the assessment of positive margins following breast cancer surgery or neoadjuvant chemotherapy, and for the assessment of breast implant integrity.

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

Year: 2017
AGREE II score: Unavailable
Developer organization: European School of Oncology
This is a clinical practice guideline for the management of patients with advanced breast cancer (ABC), including those with locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). The guideline provides recommendations for the management of these patients, and specifically discusses the use of chemotherapy, management of bone metastases, management of cancer related fatigue, as well as supportive and palliative care.

Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline From the Oncology Section of the American Physical Therapy Association

Year: 2017
AGREE II score: Disponible
Developer organization: American Physical Therapy Association
This is a clinical practice guideline for adult patients who have undergone cancer treatment, and are at risk for developing secondary upper quadrant lymphedema (SUQL). The guideline provides recommendations for the diagnosis of SUQL, using methods such as clinical examination and patient-reported symptom assessments, bioimpedance analysis, circumferential measurement, water displacement, and imaging techniques such as magnetic resonance imaging (MRI), and computed tomography (CT). The primary outcomes of interest are decreases in both morbidity as well as activity and participation restrictions, and an increase in overall quality of life (QOL).

Guidelines of Care for the Management of Cutaneous Squamous Cell Carcinoma

Year: 2017
AGREE II score: Disponible
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with cutaneous squamous cell carcinoma (cSCC). The guideline provides recommendations for the evaluation and management of patients with cSCC. Topics of interest include biopsy techniques and histopathologic assessment, tumour staging, surgical and non-surgical management, follow-up and prevention of recurrence, and management of advanced disease.

Clinical Practice Guideline on the Prevention and Management of Constipation in Children With Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Atlantic Provinces Pediatric Hematology Oncology Network
This is a clinical practice guideline for the prevention and management of constipation in pediatric cancer patients. Pharmacological and non-pharmacological treatment options (including dosing recommendations) are discussed. The management of refractory opioid-induced constipation is also examined.

EAU Guidelines on Testicular Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for the diagnosis and treatment of patients with testicular cancer. The guideline examines the pathology of the illness, staging and classification systems, diagnostic evaluation, prognosis, disease management, and follow-up. Topics of interest include diagnostic tools, treatment with chemotherapy, and discussion of quality of life and long-term toxicities after curative treatment.

Adolescent and Young Adult (AYA) Oncology, Version 2.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adolescents and young adults with cancer. The guideline discusses risk factors, screening, diagnosis, management, follow-up, supportive care, and palliative care for patients between 15 and 39 years of age. Unique issues discussed include adherence to treatment, the impact of cancer and its treatment on fertility, management of cancer during pregnancy, relationship management, and socioeconomic issues.

Prevention and Treatment of Cancer-Related Infections – Version 1.2017

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for the prevention and treatment of cancer-related infections in neutropenic and immunocompromised non-neutropenic patients with cancer. This guidelines aims to provide an overview of the risk categorization and recommended strategies for prevention of infections in high-risk patient populations, as well as monitoring in patients with signs and/or symptoms of infections. Outcomes of interest include a finding that advances in treatment further emphasize the need for multidisciplinary care.

Guidelines on the Prevention and Management of Chemotherapy Associated Diarrhea

Year: 2017
AGREE II score: Unavailable
Developer organization: Atlantic Provinces Pediatric Hematology Oncology Network
This is a clinical practice guideline for pediatric cancer patients who are receiving chemotherapy. Guidance is provided for the diagnosis and treatment of chemotherapy-induced diarrhea in these patients. Risk factors, grading of diarrhea, dietary modifications during diarrhea, and anti-diarrheal agents are also discussed.

Optimal Perioperative Care in Major Head and Neck Cancer Surgery With Free Flap Reconstruction

Year: 2017
AGREE II score: Disponible
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline for patients with head and neck cancer. The guideline examines the optimal perioperative care for patients undergoing head and neck cancer surgery with free flap reconstruction. Specific topics discussed include preadmission education, perioperative nutritional care, preoperative nutritional status, nutritional formulae, prophylaxis against thromboembolism, and antibiotic prophylaxis.

EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer

Year: 2017
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for adult patients with prostate cancer. The guideline examines the screening, diagnosis, staging, treatment, and follow-up of these patients. Treatment options considered include deferred treatment, radical prostatectomy, definitive radiotherapy, and hormonal therapy. Management of metastatic prostate cancer, prostate cancer in older men, prostate-specific antigen-only recurrence after treatment, and castration-resistant prostate cancer are also discussed, as well as the epidemiology and etiology of prostate cancer, and quality of life outcomes.

EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer

Year: 2017
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of muscle-invasive and metastatic bladder cancer. The guideline provides recommendations on prevention, staging, imaging, diagnosis, treatment, and follow-up. Treatment options such as neoadjuvant chemotherapy, radiotherapy, and radical surgery are discussed. Other topics of interest include risk factors, comorbidities, quality of life, and pelvic organ preservation techniques.

EAU Guidelines on Primary Urethral Carcinoma

Year: 2017
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with primary urethral carcinoma (UC). The guideline provides recommendations on the diagnosis and treatment of UC. Staging and classification systems for UC are also discussed. Outcomes of interest include detection rate, overall survival, complications, and toxicity.

Pneumococcal Immunization in Adult and Pedtric Patients Undergoing Cancer Treatment

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline on pneumococcal immunization for adult and pediatric cancer patients with solid tumours or hematologic cancers. The guideline provides recommendations on the type of vaccine and timing of immunization in relation to the type of treatment, therapy cycle, and severity of immunosuppression. Guidance is also provided on restrictions for immunization.

Desmoid Tumours

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with desmoid tumours. The guideline provides recommendations for diagnosis, staging procedures, treatment, and follow-up. Treatment options including active surveillance, surgery, radiation therapy, and chemotherapy are examined. Topics of interest include desmoid tumours occurring during pregnancy, pain management, and rehabilitation.

European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) Recommendations for the Surgical Management of Adrenocortical Carcinoma

Year: 2017
AGREE II score: Disponible
Developer organization: European Society of Endocrine Surgeons
This is a clinical practice guideline on the perioperative care of patients undergoing surgery for adrenocortical carcinoma (ACC). Topics covered in the guideline include the optimal preoperative investigations, surgical approach, quality criteria of the operative note and pathological report, follow-up after surgery, surgical management of metastatic and/or recurrent ACC, and debulking or palliative surgery. The guideline also emphasizes the need for inclusion in collaborative and/or prospective databases to advance research and evidence on the topic.

Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer: CHEST Guideline and Expert Panel Report

Year: 2017
AGREE II score: Disponible
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for adult patients with lung cancer who have been treated with surgery or systemic anti-cancer treatment such as chemotherapy or (external-beam) radiotherapy. The guideline provides recommendations for the symptomatic management of persistent, bothersome cough among theses patients. Multiple options for reducing cough are discussed, based on the etiology of the cough and the patient's response to various treatments.

British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice

Year: 2017
AGREE II score: Unavailable
Developer organization: British Gynaecological Cancer Society
This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.

BGCS Uterine Cancer Guidelines: Recommendations for Practice

Year: 2017
AGREE II score: Unavailable
Developer organization: British Gynaecological Cancer Society
This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.

ACR Appropriateness Criteria Suspected Liver Metastases

Year: 2017
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for the assessment of liver metastases. The guideline provides recommendations regarding the appropriateness of imaging modalities and the optimization of imaging parameters for specific clinical scenarios, including diagnosis, staging, and surveillance. Outcomes of interest include accuracy in characterizing and detecting liver lesions, length of examination, and potential adverse health effects, as well as surveillance sensitivity, specificity, and reproducibility.

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

Year: 2017
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for oncology clinicians on how to use effective communication to optimize the patient-clinician relationship, patient and clinician well-being, and family well-being. The guideline examines the core communication skills and tasks that apply across the continuum of cancer care. Topics include the discussion of goals of care and prognosis, treatment selection, end-of-life care, facilitating family involvement in care, and clinician training in communication skills.

Brain Oligometastases

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with four or fewer brain metastases. The guideline examines the important prognostic factors for assessing and managing these patients, the role of surgery and radiotherapy in the management of oligometastatic disease, and the appropriate follow-up and surveillance strategy. Treatments considered include whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS), both alone and in conjunction.

Hairy Cell Leukemia, Version 2.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with hairy cell leukemia. The guideline provides recommendations regarding diagnosis, initial treatment, response assessment and additional therapy, second-line therapy for relapsed/refractory or progressive disease, and supportive care. The impact of infections, such as hepatitis B (HBV) is also discussed.

AIDS-Related Kaposi Sarcoma, Version 1.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with AIDS-related Kaposi sarcoma. The guideline examines diagnosis, staging, treatment, and follow-up, while also providing recommendations on HIV screening and HIV therapy during cancer treatment. Antiretroviral therapy (ART), topical therapies, intralesional chemotherapy, local incisions, radiation therapy, and systemic therapy are all discussed as treatment options.

Lung Cancer Screening – Version 1.2017

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for lung cancer screening in adult patients. The guideline reviews risk factors for lung cancer and provides recommendations on selecting high-risk individuals for screening, guidance on choice of screening modalities with specific review of low dose computed tomography (LDCT), and recommendations on the evaluation and follow-up of nodules found during screening. Additionally, the benefits and risks of screening are discussed.

Cervical Cancer, Version 1.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for women with cervical cancer. The guideline examines the initial diagnosis and workup, staging, primary and adjuvant treatment, surveillance, and therapy following relapse for these patients. Treatment for metastatic disease is also discussed, as are the topics of incidental cervical cancer and the occurrence of cervical cancer in pregnant women.

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update

Year: 2017
AGREE II score: Disponible
Developer organization: International Pediatric Fever and Neutropenia Guideline Panel
This is a clinical practice guideline for the empirical management of fever and neutropenia (FN) in children with cancer, and those who have received hematopoietic stem-cell transplantation (HSCT). The guideline examines initial presentation, ongoing management, and empirical antifungal therapy. Topics of interest include risk stratification to define patients with high-risk invasive fungal disease (IFD), recommended biomarkers and radiologic investigations for the evaluation of IFD in prolonged FN, and empirical antifungal therapy in IFD low-risk patients with prolonged FN.

Breast Reconstruction Following Prophylactic or Therapeutic Mastectomy for Breast Cancer

Year: 2017
AGREE II score: Disponible
Developer organization: Alberta Health Services
This clinical practice guideline provides recommendations for breast reconstruction in women following mastectomy for the prevention or treatment of breast cancer. The guideline discusses patient education, eligibility for reconstruction, timing of reconstruction, factors that enhance recovery from reconstruction, post-reconstruction surveillance, and measuring outcomes of construction. The benefits and risks of implant-based, autologous flap, and combination reconstruction procedures are examined. The guideline also discusses the extent to appropriately perform mastectomy.

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

Year: 2017
AGREE II score: Disponible
Developer organization: American Urological Association
This is a clinical practice guideline for the management of non-metastatic muscle-invasive urothelial bladder cancer in adults. The guideline examines the initial evaluation, treatment, follow-up, and survivorship of affected patients, and discusses approaches to counseling and the role of patient preferences throughout. Specific treatment options considered include neoadjuvant and adjuvant chemotherapy, radical cystectomy, pelvic lymphadenectomy, and bladder preserving approaches such as maximal transurethral resection of bladder tumours, partial cystectomy, primary radiation therapy, and multi-modal bladder preserving therapy.

French Updated Recommendations in Stage I to III Melanoma Treatment and Management

Year: 2017
AGREE II score: Unavailable
Developer organization: French Dermatological Society
This is a clinical practice guideline for the management of stage I to III melanoma in adult patients. The guideline discusses classification, resection margins, sentinel node biopsy, adjuvant treatments, initial work-up, follow-up, and the role of molecular biology tests. The guideline also compares the recommendations provided by other European guidelines and addresses any disparities in recommendations.

Best Practices for the Management of Local-Regional Recurrent Chordoma: A Position Paper by the Chordoma Global Consensus Group

Year: 2017
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients who have received initial treatment for chordomas, who are at risk for loco-regional recurrence. The guideline provides recommendations for pre-treatment assessment, resection of recurrent or progressive disease, radiotherapy of recurrence, other local therapies, follow-up, as well as for palliative, supportive and end-of-life care. Outcomes of interest include quality of life, recurrence-free survival, and overall survival.

Guidelines of Care for the Management of Basal Cell Carcinoma

Year: 2017
AGREE II score: Disponible
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for adults who have been diagnosed with or are suspected of having basal cell carcinoma (BCC). The main focus of the guideline is on the most common approaches for the treatment of primary BCC, but it also includes recommendations on the treatment of recurrent tumours, appropriate biopsy techniques, staging, follow-up, and prevention of BCC.

Management of Infusion Reactions to Systemic Anticancer Therapy: ESMO Clinical Practice Guidelines

Year: 2017
AGREE II score: Disponible
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients who are receiving systemic anticancer therapy. The guideline examines the management of infusion reactions (IRs), which can be either allergic reactions to foreign proteins, or non-immune-mediated reactions. Specific topics discussed include risk assessment, diagnosis, management, how to document an IR, drugs which may frequently cause IRs, and cases of rechallenge.

EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (TaT1 and CIS)

Year: 2017
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of non-muscle-invasive bladder cancer. Recommendations are provided for diagnosis, staging, treatment, and follow-up. The guideline also discusses how to predict the short-term and long-term risks of disease recurrence and progression, as well as the stratification of patients into risk groups. Treatment options are presented based on these risk groups. Management of side effects is also discussed.

Guidelines for Screening and Management of Late and Long-Term Consequences of Myeloma and Its Treatment

Year: 2017
AGREE II score: Disponible
Developer organization: British Society for Haematology
This is a clinical practice guideline for patients with myeloma. The guideline examines the screening and management of physical and psychosocial consequences in these patients following completion of treatment. Recommendations are provided for long-term physical consequences, including infection and immunity, renal and urogenital complications, bone, endocrine and metabolic disorders, neurological and eye complications, cardiovascular and respiratory complications, dental and oral hygiene, gastroenterological and nutritional problems, and second primary malignancies. Psychosocial and rehabilitation considerations such as frailty, patient concerns and information provision, psychological well-being, pain and fatigue, and physical fitness and functionality are also discussed.

Cutaneous Melanoma: A National Clinical Guideline

Year: 2017
AGREE II score: Disponible
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.

Management of Chronic Myeloid Leukemia 

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline on the diagnosis, staging, treatment and management of adult patients who are suspected of having, or have been diagnosed with, chronic myelogenous leukemia (CML). Treatment options examined include the use of tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, as well as allogeneic stem cell transplant (SCT) and Interferon-a (IFNa). Special consideration is paid to the use of TKIs in the treatment of elderly patients with CML.

Oral and Dental Care Management in Head and Neck Cancer

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with head and neck cancer. The guideline examines oral and dental care assessment and management of patients before, during, and after cancer treatment. Topics addressed include pain, xerostomia, speech and swallowing disorders, oral hygiene, and functional capacity. The primary outcome of interest is quality of life.

Renal Cell Carcinoma

Year: 2017
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline examines the clinical management of RCC, including diagnosis, treatment, and follow up. The primary outcomes of interest are survival, recurrence, and quality of life.

Cancer- and Chemotherapy-Induced Anemia, Version 2.2018

Year: 2017
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adults and children with cancer-induced anemia (CIA). The guideline discusses the etiology of CIA, and examines the screening, evaluation, and treatment methods for reducing CIA in affected patients. Red blood cell transfusion, erythropoietic therapy, and iron monitoring and supplementation are discussed as treatment options.

Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline

Year: 2017
AGREE II score: Disponible
Developer organization: American Urological Association
This is a clinical practice guideline for the management of localized prostate cancer. The guideline provides a clinical framework stratified by cancer severity to guide the care plan and reviews management options including active surveillance, observation/watchful waiting, prostatectomy, radiotherapy, cryosurgery, high intensity focused ultrasound (HIFU), and focal therapy. Shared decision making is highlighted, and guidance is provided on outcome expectations and management.

Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update

Year: 2017
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adult and pediatric patients who receive antineoplastic agents or radiation therapy for cancer. The guideline examines important developments in antiemetic management options for patients undergoing the above treatments. Comparisons are made between antiemetic management options on the basis of potential benefits, potential harms, and quality of evidence. Outcomes of interest include new evidence regarding antiemetic efficacy and new antiemetic management options.

Optimal Perioperative Care in Major Head and Neck Cancer Surgery With Free Flap Reconstruction: A Consensus Review and Recommendations from the Enhanced Recovery After Surgery Society

Year: 2016
AGREE II score: Disponible
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline for patients undergoing major head and neck cancer surgery with free flap reconstruction. The guideline provides recommendations for the optimal perioperative care of these patients, focusing on topics such as preadmission education, preoperative nutritional status, perioperative nutritional care, prophylaxis against thromboembolism, antibiotic prophylaxis, postoperative nausea and vomiting prophylaxis, standard anesthetic protocol, pain management, postoperative wound care, postoperative pulmonary physical therapy, and more.

BCSH/BSBMT/UK Clinical Virology Network Guideline: Diagnosis and Management of Common Respiratory Viral Infections in Patients Undergoing Treatment for Haematological Malignancies or Stem Cell Transplantation

Year: 2016
AGREE II score: Disponible
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline for adults and children who are receiving hematopoietic stem cell transplantation (HSCT) or are undergoing treatment for hematological malignancies. The guideline provides recommendations for the diagnosis, prevention, and management of common respiratory viral infections in these patients. Diseases discussed include influenza, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), human parainfluenza virus (HPIV), and human rhinovirus (HRV).

SEOM Clinical Guideline for Gastrointestinal Sarcomas (GIST) (2016)

Year: 2016
AGREE II score: Unavailable
Developer organization: Spanish Society of Medical Oncology
This is a clinical practice guideline for the diagnosis, treatment and follow-up of patients with gastrointestinal stromal tumours (GISTs). The guideline discusses the diagnosis of GISTs using radiology, histology and molecular biology, while also providing recommendations for the treatment of both localized and advanced disease. Surgery, adjuvant and neoadjuvant treatment options are specifically examined.

The Diagnosis, Treatment, and Follow-Up of Renal Cell Carcinoma

Year: 2016
AGREE II score: Unavailable
Developer organization: German Society of Hematology and Oncology (DGHO)
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline discusses diagnosis, treatment, and follow-up, and provides specific recommendations on topics such as the primary treatment of RCC without metastases, systemic treatment for metastatic RCC, neoadjuvant/adjuvant therapy, as well as the resection and radiotherapy of metastases.

Recommendations for Symptom Management in Women With Vulvar Neoplasms After Surgical Treatment: An Evidence-Based Guideline

Year: 2016
AGREE II score: Unavailable
Developer organization:
This is a clinical practice guideline for women with vulvar cancer (VC) or vulvar intraepithelial neoplasia (VIN). The guideline provides recommendations for symptom management, with an emphasis on self-management interventions. Specific topics discussed include the handling of surgical wounds, as well as the management of acute postsurgical pain, postsurgical urinary symptoms, and lymphedema.

CGCG Clinical Practice Guidelines for the Management of Adult Diffuse Gliomas

Year: 2016
AGREE II score: Unavailable
Developer organization: Chinese Glioma Cooperative Group
This is a clinical practice guideline for adults with diffuse gliomas. Diagnosis, as well as treatment methods including chemotherapy, radiation therapy, and surgical procedures are discussed. The guideline provides general recommendations, as well as specific recommendations for low grade gliomas (WHO grade II), anaplastic gliomas (WHO grade III), and glioblastoma (WHO grade IV).

Clinical Practice Guidelines for the Management of Adult Onset Sarcoma

Year: 2016
AGREE II score: Disponible
Developer organization: Cancer Council Australia
A clinical practice guideline for the management of adult onset sarcoma. The guideline examines the diagnosis, staging, treatment, and follow-up options for sarcoma. Imaging modalities for the purpose of diagnosis and staging are compared, while the importance of multidisciplinary care and the effects of delayed referrals to specialists are discussed. In addition, pre-operative and post-operative radiotherapy are compared, and the guideline also examines adjuvant and systemic chemotherapy, as well as surgical procedures. This guideline is wiki-based and is constantly updated as new evidence arises - this review pertains to the guideline as of April 23, 2018.

Bladder Cancer – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.

Clinical Practice Guidelines for Teleoncology

Year: 2016
AGREE II score: Disponible
Developer organization: Clinical Oncological Society of Australia
This is a clinical practice guideline for teleoncology models of care. Teleoncology seeks to offer solutions to some of the access issues faced by patients and health professionals from regional, rural and remote communities around the world. The focus of the guideline is shaped by a number of clinical questions that include: what teleoncology models of care are available to health services in Australia and overseas; what models of care for teleoncology are available to nursing services; what models of care for teleoncology are available to allied health services; is teleoncology as effective as standard oncology care for the screening of cancer; is teleoncology as effective as standard oncology care for the diagnosis of cancer; is teleoncology as effective as standard oncology care for the treatment of cancer; and is teleoncology as effective as standard oncology care for the palliative care of cancer patients.

Kidney Cancer – Version 1.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with renal cell carcinoma (RCC). The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.

Hodgkin Lymphoma – Version 3.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Hodgkin lymphoma. The guideline discusses the clinical management of patients with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), focusing exclusively on patients from post adolescence through the seventh decade of life who do not have serious intercurrent disease. Areas considered and discussed within the guideline include: staging and prognosis, the role of PET scans, treatment, principles of radiation therapy, and follow-up after completion of treatment.

Esophageal and Esophagogastric Junction Cancers – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations on esophageal and esophagogastric junction (EGJ) cancers, including: a review of hereditary cancer predisposition syndromes associated with increased risk for esophageal and EGJ cancers, staging and pathology, imaging, and treatment including surgery, radiation therapy, combined modality therapy, chemotherapy, and targeted therapies. Surveillance, management of metastatic, or recurrent cancer, and best supportive care are also discussed. Special topics of interest include treatment and surveillance options for patients with Barrett's esophagus, and suggested strategies to help alleviate the current problems associated with leucovorin shortage.

Acute Lymphoblastic Leukemia – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients aged 15 or older with acute lymphoblastic leukemia (ALL). The guideline reviews diagnosis, workup and risk stratification, treatment and consolidation therapy stratified by age and Philadelphia chromosome presence/absence, surveillance, treatment for relapse/refractory disease, and supportive care. The guideline discusses typical immunophenotyping panels for all major subtypes, and minimal residual disease assessment. Evaluation and treatment of extra medullary involvement is also reviewed.

Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline provides evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Key recommendations are guided by questions including: what initial assessment is recommended before initiating any therapy for potentially curable pancreatic cancer; what is the appropriate adjuvant regimen for patients with pancreatic cancer who have undergone a resection of their primary tumor; and when should palliative care services be initiated for people with pancreatic cancer that is potentially curable by surgery.

Society of Surgical Oncology – American Society for Radiation Oncology – American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ

Year: 2016
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This guideline applies to patients with ductal carcinoma in situ (DCIS) treated with whole-breast radiation therapy (WBRT). The primary question addressed in this guideline is "what margin width minimizes the risk of ipsi-lateral breast tumor recurrence (IBTR) in patients with DCIS receiving breast-conserving surgery?" The guideline developed from a consensus panel is intended to assist treating physicians and patients in the clinical decision-making process based on the best available evidence.

ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women

Year: 2016
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for stage I breast cancer, and focuses specifically on the initial workup and surveillance for local recurrence and distant metastases in asymptomatic women. Recommendations are made with different variants in mind, including newly diagnosed cases, surveillance, and ruling out brain metastases, liver metastases, and thoracic metastases. The guideline also considers the appropriateness of different imaging procedures to detect or rule out metastasis.

Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with cancer who may be considering cardiotoxic anticancer therapies. The guideline examines surveillance and monitoring approaches for cardiac dysfunction in survivors of adult-onset cancers, both during and after treatment. Determining which patients are at risk for developing cardiac dysfunction, and identifying strategies to minimize risk before and during the administration of potentially cardiotoxic therapy, are also discussed.

European Society of Endocrinology Clinical Practice Guideline for Long-Term Follow-Up of Patients Operated on for a Phaeochromocytoma or a Paraganglioma

Year: 2016
AGREE II score: Disponible
Developer organization: European Society of Endocrinology
This is a clinical practice guideline for patients who have been operated on for a pheochromocytoma or a paraganglioma. The guideline discusses the long-term follow-up of these patients, and includes recommendations on diagnosing malignancy, perioperative work-up, duration of follow-up, monitoring methods, as well as specific considerations for pregnant women and patients who are frail and/or elderly.

Non-Hodgkin’s Lymphoma: Diagnosis and Management

Year: 2016
AGREE II score: Disponible
Developer organization: National Institutes of Health
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes: follicular lymphoma, MALT lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and peripheral T-cell lymphoma. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.

Ovarian Cancer: Diagnosis, Treatment and Follow-up

Year: 2016
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
This clinical practice guideline provides recommendations for the diagnosis, treatment, and follow-up of epithelial ovarian cancer. This guideline covers: carcinoma of the ovary, fallopian tube and primary peritoneal carcinoma; epithelial carcinoma, e.g. serious, mucinous, clear cell or endometrioid histology; borderline and invasive disease, diagnosis and first-line treatment; and follow-up after treatment. Recommendations consider patient values and preferences when treated for ovarian cancer.

Recurrent Hodgkin Lymphoma

Year: 2016
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for recurrent Hodgkin lymphoma. The guideline provides recommendations for the treatment of patients with early relapsed or progressive disease. Areas of focus include: stem cell transplantation, the role of radiation therapy, and chemotherapy.

Antiemesis – Version 2.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for antiemesis. The guideline examines emesis, types of nausea/vomiting (e.g., chemotherapy induced), antiemetic therapies, and treatment issues associated with antiemetic therapies.

Occult Primary (Cancer of Unknown Primary [CUP]) – Version 2.2017

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations for evaluation, workup, management, and follow-up of 2 pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Diagnostic tests are recommended based on disease location and patient gender. Treatment options for disseminated or localized disease for adenocarcinoma and site-specific SCC are also discussed.

Multiple Myeloma – Version 2.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for multiple myeloma. The guideline addresses diagnosis, treatment, and follow-up care. It offers specific recommendations for primary therapy, surveillance and follow-up tests for solitary plasmacytoma, smoldering (asymptomatic) myeloma, active (symptomatic) multiple myeloma, as well as for transplant and non-transplant candidates.

Gastric Cancer – Version 3.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for gastric cancer. The guideline provides an evidence- and consensus-based treatment approach for the management of patients with gastric cancer. Topic areas discussed within the guideline include: staging, principles of pathology, surgery, endoscopic therapies, radiation therapy, combined modality therapy, chemotherapy, and follow-up.

Bone Cancer – Version 1.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumors, and osteosarcoma. Surveillance and relapse is also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.

Bladder Cancer – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, and primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.

Acute Myeloid Leukemia – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations for the diagnosis and treatment of acute myeloid leukemia (AML). Induction therapy and post-remission (consolidation) therapy are reviewed with recommendations stratified by risk and age. Specific recommendations are provided for the management of acute promyelocytic leukemia (APL). The guideline also discusses therapy for relapse, evaluation and treatment of CNS leukemia, and supportive care.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for the treatment of patients with metastatic pancreatic cancer. This clinical practice guideline addresses six overarching clinical questions: After a histopathologic confirmation of pancreatic adenocarcinoma diagnosis, what initial assessment is recommended before initiating any therapy for metastatic pancreatic cancer? What is the appropriate first-line treatment of patients with metastatic pancreatic cancer? What is the appropriate therapy for patients with metastatic pancreatic cancer who experience either disease progression or intolerable toxicity with prior regimens for metastatic pancreatic cancer? When should the concept of palliative care be introduced? For patients with metastatic pancreatic cancer, what are the recommended strategies for relief of pain and symptoms? What is the recommended frequency of follow-up care/surveillance for patients with metastatic pancreatic cancer?

Non-Small Cell Lung Cancer – Version 4.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adult patients with non-small cell lung cancer. The guideline provides updated recommendations around prevention and screening, evaluation and staging, treatment, and follow up care. Areas of focus are discussed with recognition that much progress has been made in regards to screening, minimally invasive techniques for diagnosis and treatment, advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), and targeted therapies.

Prostate Cancer – Version 3.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.

Colon Cancer – Version 2.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.

Genital Tract Cancers in Females: Human Papillomavirus Related Cancers (Cervical, Vaginal & Vulvar)

Year: 2016
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing. Provincial resources are provided.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Year: 2016
AGREE II score: Disponible
Developer organization: American Thyroid Association
This is a clinical practice guideline for adult patients with thyroid nodules and differentiated thyroid cancer (DTC). The guideline provides recommendations on initial management of thyroid cancer including screening, staging, risk assessment, surgical management, radioiodine remnant ablation and therapy, and thyrotropin suppression therapy using levothyroxine, as well as long-term management including surveillance techniques, management of recurrent and metastatic disease, and consideration for clinical trials and targeted therapy. The evaluation and diagnostic approach for thyroid nodules is also discussed, including a review of indications for fine-needle aspiration biopsy and interpretation of results, as well as use of molecular markers and management of benign thyroid nodules. Outcomes of interest include survival, recurrence, sensitivity and specificity.

Cancer of the Upper Aerodigestive Tract: Assessment and Management in People Aged 16 and Over

Year: 2016
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline provides recommendations on the investigation, treatment, and follow-up care of patients aged 16 years and older with cancer of the upper aerodigestive tract. HPV-related disease and less common upper aerodigestive tract cancers including carcinoma of the nasopharynx or paranasal sinuses, unknown primary of presumed upper aerodigestive tract origin, and mucosal melanoma, are also reviewed. Additionally, recommendations are provided on optimizing rehabilitation and function. Outcomes of interest include prevalence, predictive value, sensitivity, specificity, local control, survival (overall, progression-free), treatment-related morbidity and mortality, and resource use, among others.

Myeloma: Diagnosis and Management

Year: 2016
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This guideline is for adult patients over 16 years of age with suspected, newly diagnosed, or relapsed myeloma. The guideline provides recommendations on laboratory and imaging investigations, management of newly diagnosed myeloma, managing acute renal disease caused by myeloma, preventing and managing complications, disease monitoring, and managing relapsed myeloma. Recommendations are also provided on service organization. Outcomes of interest include time to biochemical and/or clinical progression, overall survival, adverse events, quality of life and resource use.

EAU – ESTRO – SIOG Guidelines on Prostate Cancer

Year: 2016
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for male patients diagnosed with or suspected of having prostate cancer. The guideline reviews classification and staging, diagnostic evaluation, disease management, and follow-up care. Side effects of local treatment and health-related quality of life in prostate cancer survivors are also discussed. Outcomes of interest include overall survival, cancer-specific survival, development of metastatic disease, sensitivity and specificity of diagnostic procedures, and side effects of treatment.

Recommendations for Filgrastim Use in Adults by Disease Site

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline to guide appropriate prescribing of filgrastim in adults. The guidelines looks at a variety of disease sites and is intended as a guide to facilitate a shared approach to the appropriate use of filgrastim. In order provide clarity surrounding the indications in which filgrastim should be used, the recommendations are presented by disease site.

Chronic Lymphocytic Leukemia

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for adult patients with chronic lymphocytic leukemia. The guideline examines diagnosis, staging, and treatment of newly diagnosed, relapsed, and refractory leukemia. Outcomes of interest include progression-free survival, reduced adverse events, and treatment response.

Pancreatic Adenocarcinoma – Version 2.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.

Anal Carcinoma – Version 2.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Year: 2016
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This clinical practice guideline provides evidence-based recommendations to oncologists and others for treatment of patients with locally advanced, unresectable pancreatic cancer (LAPC). The guideline addresses a number of key clinical questions including: what initial assessment is recommended before initiating therapy for LAPC; what is the appropriate initial treatment approach for people diagnosed with LAPC; and for people with LAPC, what are the recommended strategies for relief of pain and symptom burden.

Small Cell Lung Cancer – Version 2.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for small cell lung cancer and lung neuroendocrine tumours. Diagnosis, staging, prognostic factors, treatment and surveillance are reviewed. Treatment options include chemotherapy, with special topics of discussion including elderly patients and second- and third-line therapies, radiotherapy (thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy), and surgery. Outcomes of interest include survival (disease free, overall, progression-free), response rates, and treatment toxicity.

ACR Appropriateness Criteria Staging of Testicular Malignancy

Year: 2016
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for the staging of testicular malignancy. Recommendations are made with consideration of the following variant: staging testis tumour, diagnosed by orchiectomy. The guideline also discusses tumour markers and provides an overview of imaging modalities.

Testicular Germ Cell Tumours

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with testicular germ cell tumours (GCTs). The guideline examines appropriate management and follow-up strategies for different stages of the two main histological types of testicular GCTs: seminomas and nonseminomas. Outcomes of interest include recurrence and overall survival.

The Society for Immunotherapy of Cancer Consensus Statement on Immunotherapy for the Treatment of Prostate Carcinoma

Year: 2016
AGREE II score: Disponible
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with prostate cancer. The guideline provides recommendations on the use of immunotherapy for the treatment of these patients, with recommendations separated based on the stage of disease (i.e. whether metastatic or non-metastatic, castration-sensitive or castration-resistant). Specific topics discussed include issues related to patient selection, monitoring of patients during and after treatment, and sequence/combination with other anti-cancer treatments.

EANO Guidelines for the Diagnosis and Treatment of Meningiomas

Year: 2016
AGREE II score: Unavailable
Developer organization: European Association of Neuro-Oncology
This is a clinical practice guideline for patients with meningiomas. Recommendations are provided regarding diagnosis, including radiological methods used, collection and storage of tissue, and histological verification. Different treatment and follow-up recommendations are also discussed, based on which World Health Organization (WHO) grade the meningioma is classified as (i.e. WHO grades I-III).

Lymphoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline addressing lymphoma in the adult population. The guideline focuses on diagnosis and pathology, staging, and treatment of Non-Hodgkin Lymphomas, Hodgkin Lymphoma, HDCT and hematopoietic stem cell transplantation for lymphoma. Supportive and follow-up care is also addressed. The guideline updates the 2015 guideline of the same title.

Smoking Cessation – Version 1.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for smoking cessation in patients with cancer. The guideline emphasizes the importance of smoking cessation in all patients with cancer and seeks to establish evidence-based, standard of care recommendations tailored to the unique needs and concerns of patients with cancer. Treatment plans are provided that include recommendations that evaluate the merits of pharmacotherapy, behaviour therapy, and follow-up. The guideline developers acknowledge that smoking and nicotine addiction is a chronic relapsing disorder and as a result, the guideline also provides recommendations around retreatment and the management of relapse.

Penile Cancer – Version 2.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.

Myelodysplastic Syndromes – Version 1.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for myelodysplastic syndromes (MDS). The guideline provides an update to recommendations on standard approaches to the diagnosis and treatment of MDS in both children and adults. The guideline discusses evaluation and prognostic stratification, Topics of interest include prognostic stratification, evaluation of related anemia and treatment of symptomatic anemia, and supportive care. Molecular abnormalities in MDS and comorbidity indices are also discussed.

Breast Cancer – Version 2.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup, staging, and treatment for both noninvasive and invasive breast cancer. Special considerations include phyllodes tumor, Paget's disease, breast cancer during pregnancy, and inflammatory breast cancer. Treatment recommendations for invasive cancer are stratified by tumor receptor status and stage. Fertility and birth control is also discussed.

2016 EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract

Year: 2016
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, upper urinary tract urothelial carcinomas (UTUCs). The guideline reviews diagnostic assessment, staging, treatment, and follow-up. Treatment recommendations are provided based on whether the disease is localized or advanced and include radical nephroureterectomy, conservative surgery, adjuvant topical agents, chemotherapy, and radiotherapy. Outcomes of interest include risk factors, sensitivity and specificity of diagnostic tests, survival (recurrence-free, disease-free, and overall), disease progression, morbidity, and mortality.

Diagnosis and Treatment of Non-muscle Invasive Bladder Cancer: AUA/SUO Guideline

Year: 2016
AGREE II score: Disponible
Developer organization: American Urological Association
This is a clinical practice guideline for patients with non-muscle invasive bladder cancer. Recommendations are provided on diagnostic procedure, risk stratification, variant histologies, urine markers, and treatment options including TURBT/Repeat resection, intravesical therapy, BCG/maintenance, and chemotherapy BCG combinations. BCG relapse and salvage regimens are reviewed as is the role of cystectomy and cystoscopy. Additionally, recommendations are provided for risk adjusted surveillance and follow-up strategies.

Acute Lymphoblastic Leukemia

Year: 2016
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the diagnosis and treatment of acute lymphoblastic leukemia in adult and pediatric patients. The guideline examines diagnostic methods, treatment by age group, and special considerations including allogeneic stem cell transplantation and the role of cranial radiation. Outcomes of interest include probability of survival and incidence of hematological relapse.

Soft Tissue Sarcoma – Version 1.2017

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for soft tissue sarcoma. The guideline examines diagnosis, treatment and follow up. Various stages are addressed, as well as a various treatment options and disease progression. Guidance is presented for specific issues (e.g., gastrointestinal stromal tumors).

Non-Hodgkin’s Lymphomas – Version 3.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Non-Hodgkin's Lymphomas (NHL). The guideline focuses on recommendations for diagnostic workup, treatment, and surveillance strategies for the most common subtypes of NHL, in addition to a general discussion on the classification systems used in NHL and supportive care considerations. The most common NHL subtypes that are covered in the guideline are: Mature B-cell lymphomas, Mature T-cell and NK-cell lymphomas, Post Transplant Lymphoproliferative Disorders (PTLD), and Castleman's Disease.

Clinical Standards for the Treatment of Rectal Cancer in Nova Scotia

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
This guideline discusses the clinical standards of care for the treatment of rectal cancer in Nova Scotia with all aspects of rectal cancer care covered, from diagnosis to survivorship and/or palliation. This includes recommended standards for professionals involved in care, pretreatment investigations, and surgical, neo-adjuvant, and adjuvant treatments. Other topics covered include lynch syndrome screening and referral to medical genetics. Psychosocial health services and supportive care recommendations are also reviewed.

Survivorship – Version 2.2016

Year: 2016
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
These clinical practice guidelines for survivorship provide screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment to aid health care professionals who work with survivors of adult-onset cancer in the post-treatment period, including those in specialty cancer survivor clinics and primary care practices. The guidelines focus on the vast and persistent impact both the diagnosis and treatment of cancer can have on the adult survivor’s health, physical and mental states, health behaviors, professional and personal identity, sexuality, and financial standing.

Cervical Cancer – Version 1.2016

Year: 2016
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

Follow-up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer

Year: 2016
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This clinical practice guideline provides recommendations for follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer. The guideline addresses the following questions which include: what evaluations (e.g., colonoscopy, computed tomography [CT], carcinoembryonic antigen [CEA], liver function, complete blood count [CBC], chest x-ray, history, physical exam) should be performed for surveillance for recurrence of cancer? What is a reasonable frequency of these evaluations for surveillance? Which symptoms and/or signs potentially signify a recurrence of CRC and warrant investigation?

Recommendations for Post-Surgical Thyroid Ablation in Differentiated Thyroid Cancer: A 2015 Position Statement of the Italian Society Of Endocrinology

Year: 2015
AGREE II score: Unavailable
Developer organization: Italian Society of Endocrinology
This is a clinical practice guideline for patients with thyroid cancer. The guideline examines the post-surgical ablation of thyroid remnant with radioactive iodine (RAI) in these patients. Preparation for RAI ablation, diagnostic RAI scanning before ablation, post-operative serum thyroglobulin (Tg) levels and neck ultrasound (US), and post-therapy whole-body scan (WBS) after remnant ablation are discussed.

Follow-up Care and Psychosocial Needs of Survivors of Prostate Cancer

Year: 2015
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for men with prostate cancer who have received treatment with curative intent. The frequency by which prostate-specific antigen (PSA) levels should be tested in these patients is discussed, and the guideline also examines appropriate diagnostic testing techniques for instances in which biochemical (BC) recurrence occurs. The guideline also discusses psychosocial issues, sexual health, fatigue, urinary health, and bowel heath outcomes associated with prostate cancer treatment.

Provincial Non-Small Cell Lung Cancer Treatment Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for the management of patients with non-small cell lung cancer. The guideline examines screening for at-risk populations, diagnostic work-up, treatment, and follow-up. Outcomes of interest include clarified current standard of care through lobectomy and mediastina lymph node dissection, with additional treatment selections based on patient population.

Provincial Oropharyngeal Cancer Treatment Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for the diagnosis, staging, and treatment of oropharyngeal cancer. The guidelines provide recommendations on staging for primary tumour, regional lymph nodes, and distant metastases; management of invasive carcinoma of oropharynx, locally advanced resectable disease; post-operative adjuvant therapy options, post chemoradiation or post radiation evaluation; salvage therapy; radiation therapy; concurrent chemotherapy; and management of residual disease, loco-regional recurrent or distant metastases.

American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline

Year: 2015
AGREE II score: Disponible
Developer organization: American Cancer Society
This is a clinical practice guideline for primary care providers, medical oncologists, radiation oncologists and other clinicians caring for female adult breast cancer survivors. The guideline provides key recommendations for breast cancer survivorship care as it relates to surveillance and screening for breast cancer recurrence, risk evaluation and genetic counseling, and laboratory tests and imaging. Additionally, the guideline discusses the nature of support survivors should be provided with to address a number of psychosocial issues including depression, body image issues, financial challenges, and cognitive impairment.

Lymphoma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline addressing lymphoma in the adult population. The guideline focuses on the following areas: Diagnosis and Pathologic Classification, Staging, Treatment of Non-Hodgkin Lymphomas, Hodgkin Lymphoma, HDCT and hematopoietic stem cell transplantation for lymphoma, supportive care in the treatment of lymphoma, and follow-up care in the treatment of lymphoma. Additionally, it seeks to provide recommendations to the following questions: what are the diagnostic criteria for the most common lymphomas; what are the staging and re-staging procedures for Hodgkin and non-Hodgkin lymphomas; what are the recommended treatment and management options for Hodgkin and non-Hodgkin lymphomas; and what are the recommended follow-up procedures for patients with malignant Hodgkin and non-Hodgkin lymphoma.

Acute Promyelocytic Leukemia

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for the diagnosis and management of acute promyelocytic leukemia (APL) in adult patients over the age of 18 years. As a unique subtype of acute myeloid leukemia (AML), APL has distinct clinical features and management when compared to other forms of AML and therefore, these guidelines serve as a supplement to the AML guidelines. The guideline recommendations are drawn from the following questions: what are the diagnostic criteria for APL; what is the recommended management for adult patients in Alberta with APL; and what is the recommended follow-up for adult patients in Alberta with APL.

Non-Hodgkin’s Lymphomas, Version 2.2015

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Non-Hodgkin's Lymphomas (NHL). The guideline focuses on recommendations for diagnostic workup, treatment, and surveillance strategies for the most common subtypes of NHL, in addition to a general discussion on the classification systems used in NHL and supportive care considerations. The most common NHL subtypes that are covered in the guideline are: Mature B-cell lymphomas, Mature T-cell and NK-cell lymphomas, Post Transplant Lymphoproliferative Disorders (PTLD), and Castleman's Disease.

Multiple Myeloma, Version 2.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for multiple myeloma. The guideline addresses diagnosis, treatment, and follow-up for patients with multiple myeloma. It offers specific recommendations for primary therapy, surveillance and follow-up tests for solitary plasmacytoma, smoldering (asymptomatic) myeloma, active (symptomatic) multiple myeloma, as well as for transplant and non-transplant candidates.

Hodgkin Lymphoma, Version 2.2015

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for Hodgkin lymphoma. The guideline discusses the clinical management of patients with classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL), focusing exclusively on patients from post adolescence through the seventh decade of life who do not have serious intercurrent disease. Areas considered and discussed within the guideline include: staging and prognosis, the role of PET scans, treatment, principles of radiation therapy, and follow-up after completion of treatment.

Acute Myeloid Leukemia, Version 1.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations for the diagnosis and treatment of acute myeloid leukemia (AML). Induction therapy and post-remission (consolidation) therapy are reviewed with recommendations stratified by risk and age. Specific recommendations are provided for the management of acute promyelocytic leukemia (APL). The guideline also discusses therapy for relapse, evaluation and treatment of CNS leukemia, and supportive care.

Dose-Dense Paclitaxel Combined With Carboplatin for Advanced/Metastatic Ovarian Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a systemic therapy summary for the use of dose-dense paclitaxel combined with carboplatintherapy to treat adults with stage 2-4 ovarian/fallopian/peritoneal cancer (with curative intent or to prolong survival). Treatment regimen, drug dose, and administration are reviewed, along with pre-medications, supportive care, suggested outpatient prescriptions, and recommendations for clinical monitoring and follow-up care. The guideline also addresses adverse events, precautions, dose modifications, and drug interactions.

Second-Line Treatment of Advanced Pancreatic Cancer with Oxaliplatin, Fluorouracil and Leucovorin (OFF Regimen)

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with advanced or metastatic pancreatic cancer. The guideline examines the use of oxaliplatin, fluorouracil and leucovorin in patients who had received, or were intolerant to, gemcitabine-based therapy. Outcomes of interest include progression-free and overall survival.

First-Line Treatment of HER2/neu Positive Locally Advanced, Recurrent or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction with Trastuzumab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with human epidermal growth factor receptor 2 (HER2)/neu positive locally advanced, recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction. The guideline examines the use of trastuzumab in conjunction with cisplatin and fluorouracil or capecitabine as a first-line treatment. Outcomes of interest include progression-free and overall survival.

First-Line Treatment of Metastatic Pancreatic Adenocarcinoma with FOLFIRINOX

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with metastatic pancreatic adenocarcinoma. The guideline examines the use of folfirinox - a combination of fluorouracil, oxaliplatin, leucovorin and irinotecan - as a first-line treatment. Outcomes of interest include progression-free and overall survival.

Evidence-Based Clinical Practice Guidelines for Management of Colorectal Polyps

Year: 2015
AGREE II score: Disponible
Developer organization: The Japanese Society of Gastroenterology
This is a clinical practice guideline for management of colorectal polyps. In recognizing an increase in the morbidity of colorectal polyp in Japan, this guideline seeks to provide recommendations for endoscopic management and surveillance after treatment. Guideline developers created a number of clinical questions and statements for the current concept and diagnosis/treatment of various colorectal polyps including epidemiology, screening, pathophysiology, definition and classification, diagnosis, treatment/management, practical treatment, complications and surveillance after treatment, and other colorectal lesions (submucosal tumors, non-neoplastic polyps, polyposis, hereditary tumors, ulcerative colitis-associated tumor/carcinoma).

Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer Adapted for Nova Scotia

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
This clinical practice guideline addresses care of adult patients with differentiated thyroid cancer, specifically within Nova Scotia. The guideline provides recommendations on pre-surgical evaluation of thyroid nodules, surgical treatment and complications, pathology reporting, grading and tumour staging (TNM), risk prognostic systems, and post-surgical radioactive iodine (RAI) therapy. Protocols for lab and diagnostic follow-up, management of local and regional recurrences, early and long-term follow-up, and supportive and palliative care management are also addressed.

American Cancer Society Colorectal Cancer Survivorship Care Guidelines

Year: 2015
AGREE II score: Disponible
Developer organization: American Cancer Society
This is a clinical practice guideline for colorectal cancer (CRC) survivors. The guideline reviews methods to identify and manage any physical and psychosocial long-term and late effects of CRC and its treatment, recommendations on surveillance for recurrence and screening for second primary cancers, and health promotion recommendations with detailed discussion about obesity, physical activity, nutrition, and smoking cessation. The guideline also discusses coordination of care among specialists and primary care providers.

ACR Appropriateness Criteria Conservative Surgery and Radiation—Stage I and II Breast Cancer

Year: 2015
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for women with stage 1 and 2 breast cancer. The guideline discusses conservative surgery and radiation therapy, while specifically examining the National Institutes of Health (NIH) Consensus Conference statement, results of prospective randomized clinical trials, patient selection and evaluation, radiation therapy (RT) following conservative surgery, treatment techniques, the role of accelerated partial-breast irradiation (PBI), the integration of radiation and adjuvant systemic therapy, and follow-up care. The guideline discusses the appropriateness of different techniques for four unique clinical situations.

2015 EAU Guidelines on Renal Cell Carcinoma (Update March 2015)

Year: 2015
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for the management of renal cell carcinoma. The guideline examines the diagnosis, staging, treatment, and follow-up of renal cell carcinoma, with treatment recommendations stratified by disease stage. Therapeutic strategies are also discussed. Outcomes of interest include overall survival, cancer-specific survival, recurrence-free survival, and quality of life.

Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Blood and Marrow Transplantation
This is a clinical practice guideline for hematopoietic stem cell transplantation for multiple myeloma. In acknowledging the fact that therapeutic strategies for multiple myeloma have changed significantly over the past decade, the guideline developers provide recommendations on the role of hematopoietic stem cell transplantation (HCT), including how to incorporate HCT and when HCT is indicated.

European Myeloma Network Guidelines for the Management of Multiple Myeloma-Related Complications

Year: 2015
AGREE II score: Unavailable
Developer organization: European Myeloma Network
A clinical practice guideline for the management of complications in patients with multiple myeloma. The guideline examines treatment and supportive care for common complications, including pain management, anemia, renal impairment, peripheral neuropathy, infections, and venous thromboembolisms. Outcomes of interest include renal failure, fracture, and reduced impairment.

ACR Appropriateness Criteria Follow-up of Malignant or Aggressive Musculoskeletal Tumors

Year: 2015
AGREE II score: Disponible
Developer organization: American College of Radiology
This is a clinical practice guideline for the follow up of malignant or aggressive musculoskeletal tumours. The guideline discusses the timing of surveillance and the type of imaging used, with a focus on FDG-PET/CT and MRI, as well as ultrasound, X-ray, and Tc-99m bone scan. Sensitivity, specificity, recurrence rate, and survival (overall and progression-free) are all considered as outcomes.

Provincial Oral Cavity Cancer Treatment Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for the treatment of oral cavity cancer. The guideline addresses staging, pre-treatment investigations. management with recommendations given by cancer stage (stage I and II, advanced (T3) and very advanced (T4B) and by site (anterior tongue, buccal mucosa, floor of mouth, retromolar trigone, and hard palate and alveolar ridge). Follow up care is also reviewed.

Guidelines for Postoperative Care in Gynecologic/Oncology Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations — Part II

Year: 2015
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
This is a clinical practice guideline for postoperative care in gynecologic/oncology surgery. The guideline reviewed existing evidence to make recommendations for elements of postoperative care. Postoperative care elements considered in the guideline include: preoperative medical optimization, bowel preparation, carbohydrate loading, thromboembolism prophylaxis, skin preparation, standard anesthetic protocol and intraoperative fluid management. This guideline is part 2 of 2 in the Enhanced Recovery After Surgery (ERAS®) Society Recommendations guidelines.

Multiple Myeloma

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is an update to the 2013 clinical practice guideline for the management of multiple myeloma in adult patients. The guideline examines diagnosis and treatment for multiple myeloma, monoclonal gammopathy, smoldering myeloma, and amyloidosis, including prognostic criteria. Outcomes of interest include improved survival outcomes through triple drug based induction regimens and improved dose reduction options for elderly patients.

Management of Cervical Cancer (Second Edition)

Year: 2015
AGREE II score: Disponible
Developer organization: Ministry of Health Malaysia
A clinical practice guideline for the management of female patients with cervical cancer. The guideline examines diagnosis, staging, treatment including surgery and adjuvant therapy, and follow up. Outcomes of interest include fertility preservations and improved quality of life through hormonal replacement therapy during follow up.

Genital Tract Cancers in Females: Human Papillomavirus Related Cancers (Cervical, Vaginal & Vulvar)

Year: 2015
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline outlines the screening, diagnosis, treatment, and follow-up of human papillomavirus related cancers. The guideline examines appropriate vaccination strategies, screening (including care controversies), and treatment including chemotherapy and surgical options. Outcomes of interest include fertility sparing and reduction of unnecessary Pap testing.

Survivorship, Version 2.2015

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
These clinical practice guidelines for survivorship provide screening, evaluation, and treatment recommendations for common consequences of cancer and cancer treatment to aid health-care professionals who work with survivors of adult-onset cancer in the post-treatment period, including those in specialty cancer survivor clinics and primary care practices. The guidelines focus on the vast and persistent impact both the diagnosis and treatment of cancer can have on the adult survivor’s health, physical and mental states, health behaviours, professional and personal identity, sexuality, and financial standing.

Smoking Cessation, Version 2.2015

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for smoking cessation in patients with cancer. These guidelines emphasize the importance of smoking cessation in all patients with cancer and seek to establish evidence-based, standard of care recommendations tailored to the unique needs and concerns of patients with cancer. These guidelines provide treatment plans that include recommendations that evaluate the merits of pharmacotherapy, behaviour therapy, and follow-up. The guideline developers acknowledge that smoking and nicotine addiction is a chronic relapsing disorder and as a result, the guideline also provides recommendations around retreatment and the management of relapse.

Penile Cancer, Version 3.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with squamous cell carcinoma (SCC) of the penis. The guideline reviews risk factors and clinical presentation, and provides recommendations for clinical staging, management of primary legions, management of regional lymph nodes, surveillance, and management of metastatic disease. Surgery, radiotherapy, and chemotherapy are reviewed as treatment options.

Occult Primary (Cancer of Unknown Primary [CUP]), Version 1.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline provides recommendations for evaluation, workup, management, and follow-up of 2 pathologic diagnoses in patients with epithelial occult primary cancer: adenocarcinoma or carcinoma not otherwise specified (NOS), and squamous cell carcinoma (SCC). Diagnostic tests are recommended based on disease location and patient gender. Treatment options for disseminated or localized disease for adenocarcinoma and site-specific SCC are also discussed.

Non-Small Cell Lung Cancer, Version 1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for adult patients with non-small cell lung cancer. The guideline provides updated recommendations around prevention and screening, evaluation and staging, treatment, and follow up. Areas of focus are discussed with recognition that much progress has been made in regards to screening, minimally invasive techniques for diagnosis and treatment, advances in radiation therapy (RT) including stereotactic ablative radiotherapy (SABR), and targeted therapies.

Kidney Cancer, Version 1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for kidney cancer. The guideline provides recommendations for the initial evaluation and staging, treatment, and follow-up for adults with various stages of kidney cancer. Topic areas discussed in the guideline include: imaging, surgery, lymph node dissection, targeted therapy, and supportive care.

Colon Cancer, Version 1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with colon cancer or adenocarcinomas of the small bowel and appendix. The guideline reviews staging, pathology, clinical presentation and treatment of nonmetastatic disease, management of metastatic disease, post-treatment surveillance, and survivorship. The role of vitamin D in colorectal cancer is also discussed.

Bone Cancer, Version1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup and treatment of bone cancer, with specific recommendations provided for chondrosarcoma, chordoma, Ewing's sarcoma family of tumours, and osteosarcoma. Surveillance and relapse are also reviewed. An overview of systemic therapy agents is provided, and principles of radiation therapy are discussed.

Bladder Cancer, Version 2.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline discusses evaluation, treatment (primary and secondary) options, and follow-up care for patients with bladder cancer. Specific workup and treatment recommendations are provided for non-muscle invasive disease, muscle invasive disease, upper genitourinary tract (GU) tumours, urothelial carcinomas of the prostate, primary carcinoma of the urethra. Non-urothelial carcinomas of the bladder are also discussed.

Anal Carcinoma, Version 1.2016

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with anal carcinoma. Risk factors are discussed and recommendations are provided on risk reduction including HIV immunization, work up, management, and follow-up care. Treatment options are reviewed, with specific recommendations provided for primary treatment of: non-metastatic anal carcinoma, anal canal cancer, and anal margin cancer, as well as treatment for metastatic cancer and for locally progressive or recurrent anal carcinoma. Special considerations are made regarding treatment of anal cancer in patients with HIV/AIDS.

Melanoma: Assessment and Management

Year: 2015
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This clinical practice guideline is for patients diagnosed with or suspected of having melanoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Follow-up care is also discussed, including topics such as management of suboptimal Vitamin D levels and concurrent drug therapies. Outcomes of interest include survival (overall, disease free, melanoma specific), and adverse events (acute toxicity, wound/sensory complications).

Acute Myeloid Leukemia

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients over the age of 18 years with acute myeloid leukemia. The guideline reviews diagnosis, classification, ancillary tests, response criteria, prognosis/risk stratification, risk groups as per cytogenetic or molecular status, and management options. Treatments reviewed include chemotherapy, hematopoietic stem cell transplantation, and palliation. Follow up care is also discussed.

Oncogenetic Testing and Follow-up for Women With Familial Breast/Ovarian Cancer, Li-Fraumeni Syndrome and Cowden Syndrome

Year: 2015
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for adult women (18 years and older) either without breast cancer or with a recent diagnosis of breast cancer, who have a family history of breast, ovarian or a related cancer; the guideline also provides recommendations for men affected by male breast cancer. The guideline discusses oncogenetic testing aspects of breast cancer and ovarian, specifically hereditary breast cancer, the Li-Fraumeni syndrome, and the Cowden syndrome. Topics include criteria and indications for genetic testing, tests for which genes have clinical utility, and appropriate follow-up depending on results and family history.

Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Japan Gastroenterological Endoscopy Society
This is a clinical practice guideline for endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR) for early gastric cancer. The guideline provides recommendations for preoperative diagnosis, evaluation of curability, management of complications, long-term postoperative surveillance, and histological assessment. The management of perforation is also specifically discussed.

Follow-up of Patients with Cutaneous Melanoma who were Treated with Curative Intent

Year: 2015
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for patients with cutaneous melanoma after treatment with curative intent. The guideline provides recommendations on follow-up schedules, involving appropriate evaluations and timing for early detection of local-regional recurrence, distant metastases, and new primary melanomas. Diagnostic imaging modalities such as ultrasound (US), computed tomography (CT), positron emission tomography (PET), and PET/CT, laboratory tests such as LDH and S100B, skin self-examinations, and dermoscopy/dermatoscopy are discussed.

Provincial Head and Neck Cancer Treatment Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for head and neck cancers, with specific epidemiological information for nasopharyngeal cancer. The guideline examines diagnostic work-up, follow-up, and treatment, primarily through systemic and chemotherapy treatments. Outcomes of interest include reduced local and distant failures through appropriate risk identification and improved regimens for induction chemotherapy.

Small Cell Lung Cancer, Version 1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for small cell lung cancer and lung neuroendocrine tumours. Diagnosis, staging, prognostic factors, treatment and surveillance are reviewed. Treatment options include chemotherapy, with special topics of discussion including elderly patients and second-line and third-line therapies, radiotherapy (thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy), and surgery. Outcomes of interest include survival (disease free, overall, progression-free) and response rates, and treatment toxicity.

Cervical Cancer, Version 2.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with cervical cancer including squamous cell carcinoma, adenosquamous carcinoma, and adenocarcinoma of the cervix. The guideline discusses diagnosis and workup, principles of staging and surgery, primary treatment, adjuvant treatment, surveillance, and therapy for relapse. Special topics of consideration include incidental cervical cancer, radiation therapy, and cervical cancer and pregnancy.

2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma

Year: 2015
AGREE II score: Disponible
Developer organization: Korean Liver Cancer Study Group (KLCSG)
This clinical practice guideline provides recommendations on prevention, diagnosis, and treatment of hepatocellular carcinoma. Treatment options are discussed including surgical resection, transplantation, local ablation, transarterial chemoembolization, external-beam radiation therapy, systemic therapies, preemptive antiviral therapy, and drug treatment for cancer pain. Assessment of tumour response and post-treatment follow-up are also reviewed.

Pulmonary Neuroendocrine (Carcinoid) Tumors: European Neuroendocrine Tumor Society Expert Consensus and Recommendations for Best Practice for Typical and Atypical Pulmonary Carcinoids

Year: 2015
AGREE II score: Unavailable
Developer organization: European Neuroendocrine Tumor Society
A clinical practice guideline for patients with pulmonary neuroendocrine (carcinoid) tumours, including typical and atypical presentations. The guideline examines diagnosis and staging, primarily through pathology and contract CT, and treatment focusing on surgical management.

Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-Small Cell Lung Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Spanish Society of Pulmonology and Thoracic Surgery
This is a clinical practice guideline fore patients who have been diagnosed with or are at risk of developing non-small cell lung cancer (NSCLC). The guideline provides recommendations on disease prevention and screening, including risk factors, the role of smoking cessation, and screening programs for early diagnosis. Recommendations regarding clinical presentation are also presented, with specific topics such as imaging studies, and surgical risk, including cardiological risk and the evaluation of respiratory function. The guideline also provides guidance on follow-up, when appropriate.

Management of Cutaneous Squamous Cell Carcinoma in Patients With Epidermolysis Bullosa: Best Clinical Practice Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with epidermolysis bullosa. The guideline provides recommendations for the diagnosis, staging, and management of cutaneous squamous cell carcinoma (SCC) in these patients. Specific topics discussed include surveillance and diagnosis, tumour evaluation and staging, surgical treatment, nonsurgical treatment, the use of prosthetics, and end-of-life care.

Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer – Updated Guidelines From the European Group on Tumor Markers

Year: 2015
AGREE II score: Unavailable
Developer organization: European Group on Tumor Markers
This is a clinical practice guideline for patients with epithelial ovarian cancer. The guideline examines the clinical use of cancer biomarkers in these patients for the purposes of screening, differential diagnosis, prognosis, and monitoring. Biomarkers discussed include cancer antigen 125 (CA125) and human epididymis protein 4 (HE4). Algorithms for calculating the risk of malignancy index (RMI) including the RMI 1, RMI 2, Assessment of Different NEoplasias (adneXa), and risk of ovarian malignancy algorithm (ROMA), are also discussed.

Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel

Year: 2015
AGREE II score: Unavailable
Developer organization: National Cancer Institute
An international panel of radiation oncologists who specialize in sarcoma reached consensus guidelines for preoperative radiation therapy (RT) for retroperitoneal sarcoma (RPS). Many of the recommendations are based on expert opinion because of the absence of higher level evidence and thus, are best regarded as preliminary. At the time of publication, the guideline developers were awaiting data from the European Organization for Research and Treatment of Cancer (EORTC) study of pre- operative radiotherapy plus surgery versus surgery alone for patients with RPS. Further data are also anticipated pertaining to normal tissue dose constraints, particularly for bowel tolerance. Nonetheless, the guidelines can be used to establish treatment uniformity to aid future assessments of efficacy and toxicity.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for Treatment of Colorectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Japanese Society for Cancer of the Colon and Rectum (JSCCR)
This is a clinical practice guideline for the treatment of colorectal cancer. The overarching aim of the guideline is to provide standard treatment strategies for colorectal cancer, to eliminate treatment disparities among institutions, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding among health-care professionals and patients. Issues addressed include: surgical treatment, treatment strategies after resection, as well as palliative care options.

2015 EAU Guidelines on Primary Urethral Carcinoma (Limited Update 2015)

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, primary urethral carcinoma. The guideline reviews diagnostic assessment, staging, and treatment. Treatment options include penile-preserving and urethral-sparing surgery, urethrectomy, radiotherapy, cisplatinum-based chemotherapy, chemoradiotherapy, transurethral resection (TUR), Bacille-Calmette-Guérin (BCG), and cystoprostatectomy with extended pelvic lymphadenectomy. Outcomes of interest include survival, sensitivity of diagnostic tests, local cure rate, local recurrence rate, and local tumour control rate.

2015 EAU Guidelines on Urothelial Carcinomas of the Upper Urinary Tract (Limited Update March 2015)

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association of Urology
This clinical practice guideline provides recommendations for urothelial carcinomas of the upper urinary tract. The guideline covers epidemiology, etiology, and pathology, staging, diagnosis, prognosis, disease management, and follow-up. Issues addressed in the guideline include: risk factors, symptoms, imaging, preoperative factors, predictive tools, and management for both localized and advanced disease.

Follow-up for Cervical Cancer

Year: 2015
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
A clinical practice guideline for female patients who have received potentially curative primary treatment for cervical cancer. The guideline examines appropriate follow-up strategies including minimum levels of screening and follow-up intervals. Outcomes of interest include recurrences detected during screening and survival rates.

Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society of Clinical Oncology
A clinical practice guideline for prostate cancer survivors. The guideline examines health promotion, screening for second primary cancers, and assessment of physical and psychosocial effects. Outcomes of interest include effective referral, minimized psychological harm, and reduced recurrence.

Evidenced-based Clinical Practice Guideline for Upper Tract Urothelial Carcinoma (Summary–Japanese Urological Association, 2014 Edition)

Year: 2015
AGREE II score: Unavailable
Developer organization: Japanese Urological Association
This is a clinical practice guideline for patients with upper tract urothelial carcinoma (UTUC). The guideline provides recommendations on diagnosis and treatment, with discussions on surgery, radiotherapy, chemotherapy and other anticancer drug therapies. Topics include surgical techniques, the use of neoadjuvant versus adjuvant chemotherapy, postoperative follow-up care, the use of ureteroscopic kidney-sparing surgery, instillation of BCG or other anticancer drugs into the upper urinary tract, treatment of metastatic or recurrent UTUC, and use of radiotherapy alone as treatment. Epidemiology is also discussed.

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: American Thyroid Association
These inaugural guidelines provide recommendations for the evaluation and management of thyroid nodules in children and adolescents, including the role and interpretation of ultrasound, fine-needle aspiration cytology, and the management of benign nodules. Recommendations for the evaluation, treatment, and follow-up of children and adolescents with differentiated thyroid cancer (DTC) are outlined and include preoperative staging, surgical management, postoperative staging, the role of radioactive iodine therapy, and goals for thyrotropin suppression. Management algorithms are proposed and separate recommendations for papillary and follicular thyroid cancers are provided.

American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts

Year: 2015
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adults with pancreatic cysts. The guideline evaluates the evidence for diagnosing and managing pancreatic cysts. Important aspects discussed in the guideline include the taking of a detailed patient history, the use of imaging, and surgery. Outcomes of interest include the prevention of mortality from cystadenocarcinoma, the appropriateness of surgical intervention, and the progression of malignancy.

Renal Cancer in Adults: Diagnosis, Treatment and Follow-up

Year: 2015
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for adult patients with renal cancer. The guideline examines treatment through surgery and ablative therapy, diagnosis, and follow-up. Outcomes of interest include improved prediction of cancer-specific survival through Karakiewicz nomograms and improved evidence for microwave ablation.

Prostate Cancer, Version 1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnostic assessment and management of prostate cancer. The guideline discusses risk stratification, molecular testing, and imaging for clinical assessment and staging workup. Management options reviewed include observation, active surveillance, radical prostatectomy, radiation therapy, androgen deprivation therapy, chemotherapy, and immunotherapy, with treatment recommendations stratified by risk. Outcomes of interest include survival and adverse effects of treatment.

Dermatofibrosarcoma Protuberans, Version 1.2016

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for dermatofibrosarcoma protuberans (DFSP). The NCCN Non-Melanoma Skin Cancer Panel has developed these guidelines outlining the treatment of DFSP to supplement their guidelines for basal cell and squamous cell skin cancers and merkel cell carcinoma. Topic areas discussed in this guideline as they relate to DFSP include: biopsy, surgery, chemotherapy, and radiotherapy.

Breast Cancer, Version 3.2015

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews workup, staging, and treatment for both noninvasive and invasive breast cancer. Special considerations include phyllodes tumour, Paget's disease, breast cancer during pregnancy, and inflammatory breast cancer. Treatment recommendations for invasive cancer are stratified by tumour receptor status and stage. Fertility and birth control are also discussed.

Endometrial Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for women with endometrial cancer, including uterine carcinosarcoma. The guideline provides recommendations on lynch syndrome screening, surgery, adjuvant treatment for completely surgically staged endometrioid carcinoma, and adjuvant treatment for surgically staged high risk histotypes including endometrial serous, clear cell, dedifferentiated/undifferentiated carcinomas and carcinosarcomas. The guideline also reviews therapy for relapsed patients, and follow-up and surveillance of women without evidence of disease after primary potentially curative treatment for any stage of endometrial cancer.

Oncogenetic Testing, Diagnosis and Follow-up in Birt-Hogg-Dubé Syndrome, Familial Atypical Multiple Mole Melanoma Syndrome and Neurofibromatosis 1 and 2

Year: 2015
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for patients at risk of Birt-Hogge-Dubé Syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2, either based on clinical suspicion or family history. The guideline reviews indications for genetic testing, clinical utility of specific genetic tests, and follow-up depending on test results and family history. Impact of genetic counselling and test on patient behaviour and distress levels is also reviewed.

Provincial Small Cell Lung Cancer Treatment Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for patients diagnosed with or suspected of having small cell lung cancer. The guideline reviews screening, work-up, and treatment for limited stage and extensive stage cancer. Recommendations are also provided on follow up care.

Hepatitis C Virus Infection Among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society for Blood and Marrow Transplantation
This is a clinical practice guideline for hematopoietic cell transplant (HCT) donors and recipients. The guideline provides recommendations on the diagnosis and management of hepatitis C virus (HCV) infection in these patients, and examines the treatment of HCV-infected donors before HCT, as well as the treatment of HCV-infected long-term HCT survivors.

Oropharyngeal, Hypopharyngeal and Laryngeal Cancer: Diagnosis, Treatment and Follow-Up

Year: 2015
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for the diagnosis, treatment, and follow-up of oropharyngeal, hypopharyngeal and laryngeal cancers. The guideline examines preferred locoregional staging methods and treatment options including an emphasis on interprofessional care. Outcomes of interest include limited evidence for the benefits of surgical treatment in some cases and some evidence that primary chemotherapy may provide some benefit over radiotherapy.

Oropharyngeal Cancer Treatment

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the diagnosis, treatment, and follow-up of oropharyngeal cancer. The guideline examines baseline assessment and imaging, and treatment options based on patient staging. Important aspects include patient treatment preference and prioritization of treatment options based on risk features.

Follow-Up Care For Early-Stage Breast Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients who have completed active medical or radiation oncology treatment for early-stage breast cancer and who have been discharged by the cancer care centre for care by the referring physician. The guideline provides recommendations on responsibilities regarding follow-up care, follow-up investigations and surveillance, and signs and symptoms indicative of a breast cancer recurrence. Potential complications from cancer treatment and common survivorship concerns and challenges are also reviewed.

Pancreatic Adenocarcinoma, Version 2.2015

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This clinical practice guideline reviews diagnosis and management of adenocarcinomas of the exocrine pancreas. Risk factors and genetic predisposition are discussed, and the guideline provides recommendations on screening, diagnosis and staging, and treatment options including systemic therapy, chemoradiation, and surgical management. Palliative and supportive care are also reviewed. Topics of interest include an overview of biomarkers, and suggestions for management of premalignant tumours of the pancreas.

Myelodysplastic Syndromes, Version 1.2016

Year: 2015
AGREE II score: Disponible
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for myelodysplastic syndromes (MDS). The guideline provides an update to recommendations on standard approaches to the diagnosis and treatment of MDS in adults. These recommendations are based on a review of recent clinical evidence that has led to important advances in treatment or has yielded new information on biological factors that may have prognostic significance in MDS.

Acute Lymphoblastic Leukemia, Version 2.2015

Year: 2015
AGREE II score: Unavailable
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients aged 15 or older with acute lymphoblastic leukemia (ALL). The guideline reviews diagnosis, workup and risk stratification, treatment and consolidation therapy stratified by age and Philadelphia chromosome presence/absence, surveillance, treatment for relapse/refractory disease, and supportive care. The guideline discusses typical immunophenotyping panels for all major subtypes, and minimal residual disease assessment. Evaluation and treatment of extra medullary involvement is also reviewed.

Cancer Of The Uterine Cervix

Year: 2015
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline examines treatment, primarily through surgery and radiotherapy, staging, and follow-up. Outcomes of interest include improved survival benefits through chemoradiotherapy and improved outcomes thought the addition of ifosamide to recommended chemotherapies.

Bladder Cancer: Diagnosis and Management

Year: 2015
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for adults age 18 years and older who are suspected of having or are newly diagnosed with bladder cancer or cancer of the urethra, or diagnosed with recurring bladder cancer or cancer of the urethra. The guideline provides recommendations on diagnosis, staging, and management of muscle-invasive, non-muscle invasive, locally advanced, and metastatic bladder cancers. Management of treatment side effects and follow-up care is also discussed. Outcomes of interest include survival (overall, disease-free), disease-related morbidity and mortality, treatment-related morbidity and mortality, psychological well-being, quality of life, admissions to hospital after diagnosis, adverse events, and cost-effectiveness.

Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer

Year: 2015
AGREE II score: Unavailable
Developer organization: American Society of Colon and Rectal Surgeons
This is a clinical practice guideline for the surveillance of patients after curative treatment of colon and rectal cancer. The guideline outlines different surveillance schedules, and offers recommendations for surveillance based on factors including: underlying risk for recurrence, patient comorbidity, and the ability to tolerate major surgery to resect recurrent disease or palliative chemotherapy, performance status, physiologic age, preference, and compliance.

Third-Line Treatment of Stage IV or Advanced, Unresectable Colorectal Carcinoma with Cetuximab

Year: 2015
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with stage IV or advanced, unresectable colorectal carcinoma. The guideline examines the use of cetuximab as a third-line therapy once other therapies, including fluoropyrimidines, oxaliplatin, or irinotecan, had been tried or when patients are intolerant to other options. Outcomes of interest include progression-free and overall survival.

2015 EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer (Limited Updated March 2015)

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline on muscle-invasive and metastatic bladder cancer. This is an update to the European Association of Urology's 2000 guidelines on bladder cancer and provides recommendations related to staging, diagnostic evaluation, management, and follow-up. Issues addressed include: imaging, surgery, chemotherapy, radiotherapy, and recurrence.

Diagnosis and Treatment of Primary CNS Lymphoma in Immunocompetent Patients: Guidelines From the European Association for Neuro-Oncology

Year: 2015
AGREE II score: Unavailable
Developer organization: European Association for Neuro-Oncology
This is a clinical practice guideline for immunocompetent adults with primary CNS lymphoma. The guideline provides consensus considerations and recommendations for diagnosis, assessment, staging, and treatment of primary CNS lymphoma. Specifically, the guideline addresses aspects of care related to surgery, systemic and intrathecal chemotherapy, intensive chemotherapy with autologous stem-cell transplantation, radiotherapy, intraocular manifestations, and management of elderly patients.

ACR Appropriateness Criteria Follow-Up and Retreatment of Brain Metastases

Year: 2014
AGREE II score: Unavailable
Developer organization: American College of Radiology
This is a clinical practice guideline for patients diagnosed and living with recurrent brain metastases. The guideline discusses different retreatment options such as whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), surgery without radiation, and chemotherapy. The guideline also examines the role of best supportive care (BSC) and the follow-up of patients, including a discussion of imaging modalities and intervals for follow-up imaging.

Italian Consensus Guidelines for the Diagnostic Work-up and Follow-up of Cystic Pancreatic Neoplasms

Year: 2014
AGREE II score: Disponible
Developer organization: Italian Association of Hospital Gastroenterologists and Endoscopists, AIGO
This clinical practice guideline provides recommendations on diagnostic assessment and follow-up for patients with cystic pancreatic neoplasms. Topics covered include indications for work-up, laboratory tests, serum markers, imaging and nuclear medicine, ultrasound/endoscopy, laboratory markers in cystic fluid, and pathology. Outcomes of interest include sensitivity and specificity, positive and negative predictive values, and accuracy of diagnostic/assessment procedures.

Lymphoma, Chronic Leukemia, Myeloma Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of hematologic cancers including amyloidosis, chronic leukemia, Hodgkin's lymphoma and other forms of lymphoma, monoclonal gammopathy of unknown significance, multiple myeloma, and solitary plasmacytoma. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, biopsy procedures, protein studies, and immunizations for this population are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Breast Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This is a clinical practice guideline for breast cancer. The guideline examines demographics and risk factors, prevention, screening and early detection, diagnosis, staging, management, and follow-up. Other important aspects explored in the guideline include: upper extremity rehab after axillary dissection, exercise for cardiovascular fitness, as well as benefits, risks, and costs. Please note that the sub-sections within this guideline were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline was accessed online.

Clinical Practice Guidelines for the Management of Adult Onset Sarcoma

Year: 2014
AGREE II score: Disponible
Developer organization: Cancer Council Australia
This is a clinical practice guideline for adults suspected of having or diagnosed with adult onset sarcoma. The guideline provides recommendations on diagnosis and staging, treatment, and follow-up care. Chemotherapy, radiotherapy, and surgery are discussed as treatment options. Outcomes of interest include local recurrence, survival (overall, long term), and quality of life.

Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for adults diagnosed with or suspected of having soft tissue or visceral sarcoma. The guideline discusses diagnosis, staging and risk assessment, and treatment stratified by whether disease type is localized or advanced. Follow-up care is also reviewed. Treatment options for patients with special presentations and entities is also discussed, including patients with retroperitoneal sarcomas, uterine sarcomas, desmoid-type fibromatosis, and breast sarcomas.

Management of Somatic Pain Induced by Head and Neck Cancer Treatment: Pain Following Radiation Therapy and Chemotherapy

Year: 2014
AGREE II score: Unavailable
Developer organization: French Otorhinolaryngology - Head and Neck Surgery Society (SFORL)
A clinical practice guideline for patients who have undergone radiation or chemotherapy for head and neck cancers. The guideline examines appropriate follow-up screening, prevention, and treatment of post-therapy pain and complications, including dental complications and neuropathy. Outcomes of interest include improved patient education and longer term screening.

Provincial Pancreatic Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with pancreatic cancer. The guideline examines assessment and treatment, primarily through radical resections including Whipple procedures. Outcomes of interest include reduced chemotherapy toxicity with gemcitabine and improved follow-up procedures.

Provincial Biliary Tract & Gall Bladder Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with biliary tract and gall bladder cancers. The guidelines examines assessment and treatment based on disease staging or re-staging, primarily thought chemotherapy or surgery. Outcomes of interest include improved nutritional supplementation and reduced need for follow-up imaging.

2014 Guidelines on Renal Cell Carcinoma

Year: 2014
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for the management of renal cell carcinoma. The guideline examines the diagnosis, staging, treatment, and follow-up of renal cell carcinoma, including updates on histology and localized disease treatment through venous thrombus. Outcomes of interest include improved management through nephron-sparing surgery and improved surveillance for small renal masses.

American Cancer Society Prostate Cancer Survivorship Care Guidelines

Year: 2014
AGREE II score: Disponible
Developer organization: American Cancer Society
This is a clinical practice guideline for prostate cancer survivors. The guideline discusses health promotion, surveillance for prostate cancer recurrence, screening for second primary cancers, long-term and late effects assessment and management, and psychosocial issues. Care coordination and implications for clinical practice are also discussed.

Diagnosis, Treatment, and Follow-up of Medullary Thyroid Carcinoma: Recommendations by the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism

Year: 2014
AGREE II score: Unavailable
Developer organization: Brazilian Society of Endocrinology and Metabolism
This is a clinical practice guideline for individuals with or suspected of having Medullary thyroid carcinoma (MTC). The guideline provides recommendations on diagnosis, surgical treatment, and follow-up care. The use of chemotherapy and/or radiotherapy in the management of individuals with metastatic MTC is also discussed. The appropriate use of RET proto-oncogene molecular testing during diagnostic assessment is discussed, and the potential value in the use of tyrosine-kinase inhibitors as a treatment option is reviewed. Outcomes of interest include survival rate (median, overall, 10-year, progression-free), sensitivity and specificity of diagnostic tests, cure rate, rate of remission, and recurrence rate.

Primary Unknown Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of metastatic cancer of unknown primary site including primarily adenocarcinomas and undifferentiated carcinomas. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, diagnostic pathology and special patient clusters are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Management of Primary Cutaneous Squamous Cell Carcinoma

Year: 2014
AGREE II score: Disponible
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients over 18 years of age with primary invasive SCC cutaneous squamous cell carcinoma. The guideline reviews risk factors, staging, therapeutic interventions, and follow-up care. Outcomes of interest include prognostic factors, survival (five-year overall and recurrence free), local control, recurrence rate (regional and distant), nodal metastases, effectiveness of treatment, and adverse events.

Colon Cancer: Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
This is a clinical practice guideline for adult patients diagnosed with or suspected of having colon cancer. The guideline provides recommendations on diagnostic assessment and staging, pathology, treatment, and follow-up care. The use of KRAS mutational analysis and BRAF are reviewed, and N-RAS and MSI are discussed as predictors of treatment effectiveness. Comparisons are made between chemotherapy regimes, surgical techniques, and recovery programs. Outcomes of interest include sensitivity and specificity of diagnostic tests, survival (progression-free, overall), surgical outcomes (mortality, complications, readmissions, hospital stay, peri-procedural morality), and quality of life.

Prophylaxis and Treatment of Venous Thromboembolism in Patients Undergoing Treatment for Solid Tumours

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for ambulatory and inpatients undergoing treatment for solid tumours, at risk for venous thromboembolism. The guideline examines appropriate surveillance and follow up, and treatment through anticoagulants. Outcomes of interest include improved recommendations for the elderly and clarified preoperative medication timelines.

Management of Malignant Pleural Effusion

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with suspected or diagnosed malignant pleural effusions. The guideline examines diagnosis and treatment for symptomatic and asymptomatic patients, including therapeutic thoracentesis. Outcomes of interest include improved relief of dyspnea and reduced hospital stay time.

Adenocarcinoma of the Pancreas

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with pancreatic cancer. The guideline reviews diagnostic work-up, staging, and treatment options for both potentially curable and unresectable pancreatic cancer. Comparisons are made between FOLFIRINOX and gemcitabine chemotherapy regimes. Outcomes of interest include survival, adverse events, and response rate.

Medulloblastoma

Year: 2014
AGREE II score: Disponible
Developer organization: Alberta Health Services
A clinical practice guideline for the treatment of newly diagnosed and recurrent or relapsed medulloblastoma in adult patients. The guideline examines MRI workup, surgery with maximal safe resection, and management of localized and non-localized recurrence. Outcomes of interest include improved long-term survival rates with maximal excision and improved local control with postoperative radiotherapy.

Management of Recurrent High-Grade Gliomas

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over the age of 18 years with recurrent high-grade gliomas, including grade III anaplastic astrocytomas, anaplastic oligodendrogliomas, anaplastic oligoastrocytomas and grade IV glioblastomas. The guideline discusses diagnostic assessment for recurrence, and treatment options including systemic therapy, surgery, and re-irradiation. Factors of consideration when determining treatment course are also discussed.

Care of the Pediatric Patient With a Brain Tumour

Year: 2014
AGREE II score: Unavailable
Developer organization: American Association of Neuroscience Nurses
A clinical practice guideline for pediatric brain tumour patients, specifically for nursing activities. The guideline examines management of brain tumour diagnosis and treatment, including symptom management and supportive care. Outcomes of interest include improved nursing surveillance of neurological and hereditary cognitive symptoms.

Care of the Adult Patient With a Brain Tumour

Year: 2014
AGREE II score: Unavailable
Developer organization: American Brain Tumor Association
A clinical practice guideline for adult patients with brain tumours, specifically focusing on nursing activities. The guideline examines management from diagnosis to survivorship or end-of-life care, with specific focus on symptom management and communication with patients and family. Outcomes of interest include improved patient education and supportive communication..

Management of Patients With Early Esophageal Cancer, Dysplastic and Non-Dysplastic Barrett’s Esophagus

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for the management of patients with early esophageal cancer, dysplastic and non-dysplastic Barrett's esophagus. This guideline examines treatment options and considers in what clinical situations endoscopic therapy is the most appropriate treatment. Treatment options explored and discussed include: endoscopic mucosal resection, radiofrequency ablation, photodynamic therapy, argon plasma coagulation, and multipolar electrocoagulation.

Genital Tract Cancers in Females: Endometrial Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for female patients aged 19 and older. The guideline provides recommendations on the screening, diagnosis, treatment, and follow-up care of endometrial cancer. Prevention and risk reduction strategies are also discussed.

British Thyroid Association Guidelines for the Management of Thyroid Cancer

Year: 2014
AGREE II score: Disponible
Developer organization: British Thyroid Association
A clinical practice guideline for the management of patients with differentiated and medullary thyroid cancer. The guideline examines the management of thyroid cancer from diagnosis to follow-up, with specific focus on radioiodine remnant ablation and appropriate post-treatment follow-up. Outcomes of influence include improved outcomes in total thyroidectomy and improved personalised decision making.

Provincial Hepatocellular Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult and pediatric hepatocellular cancer patients. The guideline examines assessment and treatment for both curative and non-curative therapies. Outcomes of interest include clarified follow-up timing and early involvement of supportive care.

Treatment of Borderline Resectable and Locally Advanced Pancreatic Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: Eastern Health
This is a clinical practice guideline for patients diagnosed with borderline resectable or locally advanced pancreatic cancer. The guideline reviews pre-treatment staging, therapeutic options including biliary decompression and neoadjuvant therapy, chemotherapy with and without gemcitabine, chemoradiation therapy (CRT), induction chemotherapy and CRT, and radiological re-evaluation. Outcomes of interest include survival (median, overall, progression-free), treatment toxicity, adverse events, and surgical resectability rates.

2014 Guidelines on Penile Cancer

Year: 2014
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for the management of penile cancers in adult male patients, focusing primarily on penile squamous cell carcinoma. The guideline examines the full continuum of cancer care for penile cancer patients, and provides a variety of treatment options based on staging and diagnosis. Outcomes of interest include improved functional and cosmetic treatment and reduced nodal recurrence.

British HIV Association Guidelines for HIV-Associated Malignancies 2014

Year: 2014
AGREE II score: Disponible
Developer organization: British HIV Association
This is a clinical practice guideline for the diagnosis and treatment of cancer and associated malignancies in adult patients with HIV. The guideline examines the most common HIV associated cancers, Kaposi sarcoma, high grade B-cell non-Hodgkin lymphoma and invasive cervical cancer, as well as a number of other cancers with higher risk profiles in HIV patients. Outcomes of interest include improved treatment options in consideration of HAART and increased prophylactic options in low-risk patients, specifically with regards to lifestyle changes and vaccinations.

Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS)

Year: 2014
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for non-muscle-invasive bladder cancer patients with Ta, T1, and CIS grade tumours. The guideline examines diagnosis and treatment with a particular focus on adjuvant treatment options. Outcomes of interest include reduced recurrence with smoking cessation, and improved early detection through imaging.

Guidelines on Prostate Cancer

Year: 2014
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for prostate cancer patients, particularly older men. The guideline examines diagnosis, staging, treatment and follow up, primarily for locally advanced and metastatic cancers. Outcomes of interest include improved functional outcomes and improvements in deferred treatment.

Management of Somatic Pain Induced by Treatment of Head and Neck Cancer: Postoperative Pain

Year: 2014
AGREE II score: Unavailable
Developer organization: Guidelines of the French Oto-Rhino-Laryngology - Head and Neck Surgery Society (SFORL)
This is a clinical practice guideline for head and neck cancer. The guideline considers the management of somatic pain induced by the treatment of head and neck cancer, particularly the management of early and late post-surgical pain. Areas of interest discussed in the guideline include: patient positioning during surgery, how to proceed during the immediate postoperative period, care-related pain, and physical therapy.

Neuro-Oncology Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of neurological cancers including five primary subgroups: astrocytoma, oligodendroglioma, ependymoma, meningioma, and pituitary adenoma. Topics of discussion include prevention, diagnosis and staging, management, and follow-up. Additionally, the use of corticosteroids and anticonvulsants are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Fertility Preservation for AYAs Diagnosed With Cancer: Guidance for Health Professionals

Year: 2014
AGREE II score: Disponible
Developer organization: Cancer Council Australia
This is a clinical practice guideline for adolescents and young adults - aged between 15 and 24 years of age - diagnosed with cancer of any type. The guideline reviews fertility discussions between practitioner and patient, options for fertility preservation, impact of treatments on fertility, and long term follow-up. Additional links for patient and practitioner resources are also provided.

Endometrial Cancer: A Review and Current Management Strategies: Part II

Year: 2014
AGREE II score: Unavailable
Developer organization: Society of Gynecologic Oncology
This is a clinical practice guideline for women with endometrial carcinoma. The guideline reviews treatment options including: adjuvant therapy including radiation, vaginal brachytherapy, and chemotherapy; and therapy for advanced disease. Treatment for synchronous endometrial and ovarian cancer, fertility-sparing treatment, post-treatment patient surveillance, and the role of hormone replacement therapy in the development of endometrial carcinoma are also discussed. Outcomes of interest include survival (overall, 5-year, disease-specific), locoregional recurrence rate, survival rate after recurrence, and toxicity.

Oral Cavity Cancer: Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for patients with oral cavity cancers. The guideline examines diagnosis, treatment, and follow-up with a focus on radiotherapy and appropriate imaging techniques. Outcomes of interest include improved supportive care through nutritional therapy and improved follow-up timing.

Optimizing Adequacy of Bowel Cleansing for Colonoscopy: Recommendations From the US Multi-Society Task Force on Colorectal Cancer

Year: 2014
AGREE II score: Disponible
Developer organization: US Multi-Society Task Force on Colorectal Cancer
A clinical practice guideline for adult and paediatric patients undergoing colonoscopies for cancer surveillance. The guideline examines appropriate bowel cleansing procedures, including dietary recommendations and salvage options. Outcomes of interest include improved OTC purgative prescription and greater use of low-volume agents.

Uveal Melanoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with malignant uveal melanoma. The guideline reviews diagnosis and work-up, primary management, adjuvant therapy, management of patients with metastatic disease, and management of high risk patients. Follow-up care is also discussed. Outcomes of interest include efficacy of treatments and imaging modalities.

Update of the European Guidelines for Basal Cell Carcinoma Management

Year: 2014
AGREE II score: Unavailable
Developer organization: European Dermatology Forum
This is a clinical practice guideline for patients diagnosed with or suspected of having basal cell carcinoma. The guideline reviews prognosis and risk factors, diagnosis, treatment, follow-up care, and prevention. Outcomes of interest include cure rate, recurrence, cost-effectiveness, and response rate.

Timing and Extent of Thyroid Surgery for Gene Carriers of Hereditary C Cell Disease – A Consensus Statement of the European Society of Endocrine Surgeons (ESES)

Year: 2014
AGREE II score: Unavailable
Developer organization: European Society of Endocrine Surgeons (ESES)
This is a clinical practice guideline for patients who are Rearranged during Transfection (RET) proto-oncogene mutation carriers. The guideline provides recommendations on the timing and extent of thyroid surgery. Recommendations are stratified by patient risk with considerations made to genetic characteristics, patient age at diagnosis, and calcitonin levels at the time of decision making. Postoperative management and follow-up is also discussed. Outcomes of interest include risk of metastasis and risks of extended surgery (including permanent hypoparathyroidism and permanent paralysis of the recurrent laryngeal nerve).

British Society of Gastroenterology Guidelines on the Diagnosis and Management of Barrett’s Oesophagus

Year: 2014
AGREE II score: Disponible
Developer organization: British Society of Gastroenterology
This is a clinical practice guideline for Barrett’s oesophagus and related early neoplasia. The guideline provides recommendations to guide patient management. The guideline addresses issues in Barrett’s oesophagus including: definition, screening and diagnosis, surveillance, pathological grading for dysplasia, management of dysplasia, and early cancer including training.

Minimally Invasive Follicular Thyroid Cancer (MIFTC) – A Consensus Report of the European Society of Endocrine Surgeons (ESES)

Year: 2014
AGREE II score: Disponible
Developer organization: European Society of Endocrine Surgeons (ESES)
This is a clinical practice guideline for minimally invasive thyroid carcinoma (MIFTC). The guideline considers recommendations in the management of patients with MIFTC. Topics of consideration include: MIFTC definition, specimen processing, characteristics, diagnosis, prognoses, and therapy. Also of interest in the guideline is the distinction between MIFTC and widely invasive follicular thyroid carcinoma (WIFTC).

Head and Neck Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of head and neck cancers including oral and dental care. Topics of discussion include predisposing factors, prevention, screening, early detection, diagnosis and staging, management, and follow-up. Additionally, oral care through chemotherapy, radiation therapy, and bone marrow transplantation are discussed. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Gynecology Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on the management of gynecologic cancers including gynecological sarcomas and cancers of the ovary (epithelial and non-epithelial carcinomas), endometrium, uterine cervix, vulva, fallopian tube, gestational trophoblastic neoplasia, and vagina. Topics of discussion include diagnosis and staging, management, and follow-up. Additionally, prevention and screening are discussed for ovarian, endometrial, and cervical cancers. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Gastrointestinal Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: BC Cancer Agency
This guideline set provides recommendations on gastrointestinal cancer, with sub-sections discussing the following tumour sites: anus, bile duct, colon, esophageal and esophagogastric junction, gallbladder, liver, neuroendocrine tumours, lymphoma, gastro-intestinal stromal tumours (GIST), pancreas, rectum, small bowel, and stomach. Important aspects discussed in the guideline include: screening, diagnostic and staging, surgical therapy, staging, follow up and surveillance, and considers different treatment options. Please note that the sub-sections within this set were published and revised at varying dates, and that the publication year referenced here refers only to the date that the guideline set was accessed online.

Comprehensive Cervical Cancer Control: A Guide to Essential Practice – 2nd Ed

Year: 2014
AGREE II score: Unavailable
Developer organization: World Health Organization
This clinical practice guideline discusses cervical cancer control including: cervical cancer prevention and control programmes; community mobilization, education and counselling; HPV vaccination; screening and treatment of cervical pre-cancer; diagnosis and treatment of invasive cervical cancer; and palliative care. Treatment options for special populations including women who are pregnant and women living with HIV are also reviewed.

Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Year: 2014
AGREE II score: Unavailable
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline endorsement on adjuvant and salvage radiotherapy after prostatectomy. The guideline examines management of localized prostate cancer with adjuvant radiotherapy after prostatectomy compared to radical prostatectomy only. Aspects of interest include: adverse pathologic findings at prostatectomy, the risk of biochemical prostate-specific antigen (PSA) recurrence, and clinical progression of cancer.

Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines

Year: 2014
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline endorsement for people at risk for hereditary colorectal cancer (CRC) syndromes. The guideline provides recommendations on prevention, screening, genetics, treatment, and management. Topics of interest addressed in the guideline include: tumour testing for DNA mismatch repair (MMR) deficiency, genetic testing for Lynch syndrome, as well as follow-up recommendations in mutation carriers.

Management of Primary Germ Cell Tumours of the Central Nervous System

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over the age of 18 years with primary germ cell tumours (GCTs) of the central nervous system. The guideline discusses staging and diagnosis, treatment, and follow-up care. Recommendations for treatment options are provided for germinoma and nongerminomatous GCT, and are stratified by whether disease is localized or metastatic. Additional recommendations are made for recurrent treatment, again stratified by histology.

Genital Tract Cancers in Females: Human Papillomavirus Related Cancers (Cervical, Vaginal & Vulvar)

Year: 2014
AGREE II score: Unavailable
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for female patients aged 9 and above. The guideline provides recommendations on screening, diagnosis, treatment, and follow-up care of human papillomavirus (HPV) related cancers including cervical, vaginal, and vulvar. Special topics of interest include an overview of HPV vaccines and a discussion on controversies in care, including screening intervals and age to stop screening.

Prostate Cancer: Diagnosis and Treatment

Year: 2014
AGREE II score: Disponible
Developer organization: National Institute for Health and Care Excellence
This is a clinical practice guideline for men with suspected or diagnosed localised, locally advanced, or metastatic prostate cancer. The guideline examines diagnosis and staging, primarily through PSA testing and biopsy, as well as timelines for active surveillance options. The guideline also examines multiple treatment options based on cancer staging, including hormone therapy, radiotherapy, and radical surgical options. Outcomes of interest include increased prediction of outcomes, overall survival, and reduced risk of bone density loss.

Management of Stage I Seminoma

Year: 2014
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with stage 1 testicular seminoma. The guideline outlines treatment options including radiotherapy and chemotherapy, and provides recommendations on follow-up surveillance. Outcomes of interest include cancer-specific survival, long-term toxicity (including second malignancy), and quality of life.

Saudi Oncology Society Clinical Management Guideline Series: Gastric Cancer 2014

Year: 2014
AGREE II score: Unavailable
Developer organization: Saudi Oncology Society
A clinical practice guideline for patients with esophagogastric junction tumour. The guideline examines staging, pre-treatment evaluation, treatment through surgery and adjuvant therapy, and basic follow-up. Important aspects include surgical pathology report requirements and post-operative management.

Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline

Year: 2014
AGREE II score: Unavailable
Developer organization: The Endocrine Society
This is a clinical practice guideline for patients suspected of having or diagnosed with pheochromocytoma and paraganglioma (PPGL). Recommendations are provided for diagnostic biochemical testing, imaging studies, genetic testing, perioperative medical management, and surgery. The guideline also discusses personalized management of PPGLs with recognition of the distinct genotype-phenotype presentations of hereditary PPGLs. Outcomes of interest include sensitivity of diagnostic tests, rates of metastasis or recurrence after treatment, and peri- and post-operative complications.

When to Perform a Pancreatoduodenectomy in the Absence of Positive Histology? A Consensus Statement by the International Study Group of Pancreatic Surgery

Year: 2014
AGREE II score: Unavailable
Developer organization: International Study Group of Pancreatic Surgery (ISGPS)
This is a clinical practice guideline for localized pancreatic head cancer. The guideline examines when to perform a pancreatoduodenectomy (PD) in the absence of positive histology. Other important aspects discussed in the guideline include: the issue of the preoperative biopsy, pancreatitis, and neuroendocrine neoplasms.

Anal Cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2014
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients diagnosed with or at risk of having anal cancer. The guideline outlines screening and prevention, diagnostic assessment and staging, treatment, and follow-up and surveillance. Special topics of interest include treatment of the elderly and personalized medicine. Management of advanced/metastatic disease is also discussed. Outcomes of interest include survival, recurrence rates and quality of life.

Follow-Up Surveillance of Soft Tissue Sarcoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients who have undergone treatment for soft tissue sarcomas. The guideline examines appropriate surveillance and follow up methods, including regular imaging and physical examination. Outcomes of interest include preference for x-rays over MRI or CT, and increased postoperative imaging.

Oral Cavity Cancer

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with suspected or diagnosed oral cavity cancer. The guideline examines diagnosis, treatment, and potential reconstruction depending on cancer stage and site-specificity. Outcomes of interest include improved functional outcomes through reconstruction and improved adjuvant therapy for patients with increased risk factors.

Hepatocellular Carcinoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with hepatocellular carcinoma. The guideline provides recommendations on diagnostic assessment, staging, and management. Treatment options including resection, liver transplantation, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI), transarterial chemo-embolization (TACE), transarterial radioembolization (TARE), sorafenib, and stereotactic body radiotherapy (SBRT) are reviewed.

Stages II and III Colorectal Cancer Surveillance

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over the age of 18 years with stage II or III colorectal cancer. The guideline discusses follow-up care and provides recommendations regarding the timing and appropriateness of surveillance tests/procedures including CEA testing, colonoscopy, PET scans and CT scans. The guideline also discusses how physicians can educate patients about adopting healthy lifestyle behaviours to improve survival outcomes.

Neo-Adjuvant (Pre-Operative) Therapy for Breast Cancer – General Considerations

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients 18 years or older with non-metastatic breast cancer. The guideline discusses neo-adjuvant therapy for breast cancer, including eligibility, advantages and dis-advantages, available therapies. Optimal treatment monitoring, surgical considerations, and the role of radiotherapy are also discussed. Outcomes of interest include prognostic factors, response rate, accuracy of diagnostic procedures, survival (disease-free, overall), and relapse rate.

Adjuvant Interferon for Malignant Melanoma

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults with malignant melanoma. The guideline considers whether adjuvant interferon alpha should be offered to patients who have been rendered disease-free following the resection of cutaneous melanomas and who are at high risk for subsequent recurrence. Issues discussed include: steps of treatment, potential side effects, special considerations (such as toxicity, and patient education), and follow-up.

The Role of Imaging in the Management of Progressive Glioblastoma: A Systematic Review and Evidence-based Clinical Practice Guideline

Year: 2014
AGREE II score: Disponible
Developer organization: Joint Guidelines Committee of the Congress of Neurological Surgeons and American Association of Neurological Surgeons
This is a clinical practice guideline for adult patients with previously diagnosed glioblastoma who are suspected of experiencing progression of the neoplastic process. The guideline provides recommendations on surveillance imaging techniques for determining tumour progression. Outcomes of interest include accuracy, sensitivity, specificity, and positive and negative predictive values.

Provincial Esophageal and Gastro-Esophageal Junction Cancer Treatment Guidelines

Year: 2014
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with esophageal cancer and gastro-esophageal junction cancer. The guideline examines diagnostic assessment and proposed treatment based on cancer staging, with a focus on chemoradiation and surgical therapies. Outcomes of interest include improved recommendations for patients with good and poor performance.

Follow-up and Surveillance of Curatively Treated Lung Cancer Patients

Year: 2014
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
A clinical practice guideline for patients with small cell and non-small cell lung cancer who have undergone curative treatment. The guideline examines screening and disease control through imaging and follow-up visits to prevent recurrence. Outcomes of interest include increased follow-up recommendations for the first two years after treatment, when recurrence is most likely to occur.

Chronic Lymphocytic Leukemia

Year: 2014
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients over 18 years of age with possible chronic lymphocytic leukemia. The guideline reviews the management of chronic lymphocytic leukemia, including diagnosis and prognosis, first-line and second-line treatment options, and follow-up and supportive care. Outcomes of interest include survival (overall and progression-free), toxicity, overall response, and quality of life.

Malignant Melanoma S3-Guideline « Diagnosis, Therapy and Follow-up of Melanoma »

Year: 2013
AGREE II score: Unavailable
Developer organization: German Cancer Society (DKG)
This is a clinical practice guideline concerning the diagnosis, therapy and follow-up of melanoma. The guideline examines such treatment options as excision, adjuvant therapy with interferon-alpha, and lymphadenectomy. In addition, new immunotherapies such as the CTLA-4 antibody ipilimumab are considered, and follow-up procedures are discussed.

Anal Canal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adults over 18 years of age with squamous cell carcinomas that arise in the anal canal. The guideline discusses diagnostic work-up, staging, and the goals of therapy and recommendations for both potentially curable, locally recurrent, and metastatic cancer of the anal canal. Follow-up care is also reviewed.

European Experts Consensus Statement on Cystic Tumours of the Pancreas

Year: 2013
AGREE II score: Unavailable
Developer organization: European Study Group on Cystic Tumours of the Pancreas
A clinical practice guideline for patients with cystic tumours of the pancreas. The guideline examines the diagnosis and management of pancreatic tumours, including assessment of biopsy and surgical assessment. Outcomes of interest include improved diagnostic imaging and improved follow-up.

Magnetic Resonance Imaging for the Clinical Management of Rectal Cancer Patients: Recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Consensus Meeting

Year: 2013
AGREE II score: Unavailable
Developer organization: European Society of Gastrointestinal and Abdominal Radiology (ESGAR)
This clinical practice guideline reviews the use of MRI for primary clinical staging or restaging of rectal cancer. The guideline provides recommendations on MRI requirements and sequences, criteria for MRI assessment, and MRI reporting. Imaging techniques including endorectal ultrasound, computed tomography (CT), and positron emission tomography (PET) are also discussed.

Provincial Vulva Cancer Treatment Guidelines

Year: 2013
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult patients with squamous cell carcinoma of the vulva. The guideline examines management of vulvar cancer based on staging, and follow-up protocols. Outcomes of interest include endorsement of sentinel lymph node biopsy as a standard of care and improved referral recommendations.

Nonmuscle Invasive Bladder Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of patients with nonmuscle invasive bladder cancer, identified as stages Tis, Ta, and T1. The guideline examines adjuvant therapy, recurrence prevention, and appropriate follow-up, with specific focus on maintenance therapy and treatment failure. Outcomes of interest include improved recommendations for bacillus calmette-guerin therapy and its use in improved maintenance therapy.

Nasopharyngeal Cancer Treatment

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of patients with, or suspected of having, nasopharyngeal cancer. The guideline examines baseline investigation procedures, treatment options with a specific focus on radiotherapy, and follow-up. Outcomes of interest include improved treatment strategies for advanced stage patients, and improved concurrent chemotherapy options.

Follow-Up Care for Early-Stage Breast Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients who have completed treatment for early-stage breast cancer. The guideline examines surveillance follow-up for potential recurrence, with specific focus on potential complications from previous treatment. Outcomes of interest include improved management of endocrine therapy complications and improved lymphadema management.

Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients over 18 years of age with epithelial ovarian cancer. The guideline provides treatment recommendations with consideration to stage, grade, and tumour type. Treatment options are discussed including various chemotherapy regimes, surgery, and radiotherapy. Treatment of recurrent disease and post-treatment follow up and surveillance are also reviewed. Outcomes of interest include overall and progression-free survival, and clinical remission.

Guidelines on Primary Urethral Carcinoma

Year: 2013
AGREE II score: Disponible
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, primary urethral carcinoma. The guideline reviews diagnostic assessment, staging, and treatment. Treatment options include penile-preserving and urethral-sparing surgery, urethrectomy, radiotherapy, cisplatinum-based chemotherapy, chemoradiotherapy, transurethral resection (TUR), Bacille-Calmette-Guérin (BCG), and cystoprostatectomy with extended pelvic lymphadenectomy. Outcomes of interest include survival, sensitivity of diagnostic tests, local cure rate, local recurrence rate, and local tumour control rate.

Guidelines on Urothelial Carcinomas of the Upper Urinary Tract

Year: 2013
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for patients with, or suspected of having, upper urinary tract urothelial carcinomas (UTUCs). The guideline reviews diagnostic assessment, staging, treatment, and follow-up. Treatment recommendations are provided based on whether the disease is localized or advanced, and include radical nephroureterectomy, conservative surgery, adjuvant topical agents, chemotherapy, and radiotherapy. Outcomes of interest include risk factors, sensitivity and specificity of diagnostic tests, survival (recurrence-free, disease-free, and overall), disease progression, morbidity, and mortality.

Endometrial Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with endometrial cancer including uterine carcinosarcoma. The guideline examines treatment options including surgery, radiotherapy, chemotherapy and hormone therapy. Therapy for relapse and follow-up and surveillance care are also reviewed. Outcomes of interest include recurrence, 5-year progression-free survival, 5-year overall survival, and toxicity.

Long Term Follow up of Survivors of Childhood Cancer

Year: 2013
AGREE II score: Disponible
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients who were treated for cancer as a child or teenager and who may be at risk of developing late effects that are largely, but not exclusively, related to the cancer treatment they received. The guideline reviews the identification, assessment, and management of treatment related late effects. Outcomes of interest include risk of developing late effects including subsequent primary cancers, fertility issues, cardiac effects, bone health, metabolic syndrome, cognitive and psychosocial outcomes, growth problems, dental and facial problems, and thyroid dysfunction.

First-Line Treatment of Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) with Fludarabine, Cyclophosphamide, and Rituximab (FCR Regimen)

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
A clinical practice guideline for patients with newly diagnosed chronic lymphocytic leukemia (CLL). The guideline examines first-line treatment of CLL with fludarabine, cyclophosphamide, and rituximab (FCR Regimen). Outcomes of interest include progression-free and overall survival.

Recommendations for Breast Cancer Surveillance for Female Survivors of Childhood, Adolescent, and Young Adult Cancer Given Chest Radiation

Year: 2013
AGREE II score: Disponible
Developer organization: International Late Effects of Childhood Cancer Guideline Harmonization Group
This is a clinical practice guideline for breast cancer surveillance for female survivors of childhood, adolescent, and young adult (CAYA) cancer given chest radiation. The guideline examines the risk survivors of CAYA cancer of premature morbidity and mortality due to previous cancer treatment. Outcomes of interest include surveillance, detection, and follow-up.

Supportive Care after Curative Treatment for Breast Cancer (Survivorship Care): Resource Allocations in Low- and Middle-income Countries

Year: 2013
AGREE II score: Unavailable
Developer organization: Breast Health Global Initiative
This guideline discusses supportive care of patients after they have received curative treatment for breast cancer. The guideline recommendations are geared towards patients in low- or middle-income countries. Recommendations are provided on health education, community awareness, and psychosocial patient-support after curative treatment, as well as management of survivorship issues including long-term complications, lifestyle modifications, and monitoring and documentation following curative treatment.

2013 European Thyroid Association Guidelines for Cervical Ultrasound Scan and Ultrasound-Guided Techniques in the Postoperative Management of Patients with Thyroid Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: European Thyroid Association
This clinical practice guideline examines the use of cervical ultrasound scanning (US) in the postoperative management of patients with differentiated thyroid cancer of follicular origin. Topics of interest include recommendations on US procedure including fine needle aspiration technique, differentiation of benign and pathological US patterns, and indications for cervical ultrasound, US-FNA, and in situ biological marker assessment. New methods for preoperative localization of cervical recurrence and alternatives to surgical treatment of cervical recurrence are also discussed. Outcomes of interest include sensitivity, specificity, predictive value, and accuracy of ultrasound scanning.

Breast Cancer: Management and Follow-up

Year: 2013
AGREE II score: Unavailable
Developer organization: Guidelines and Protocols Advisory Committee
This is a clinical practice guideline for women over 19 years of age who have biopsy-proven breast cancer. The guideline provides recommendations on specialist referral, treatment, and follow-up care including surveillance for breast cancer recurrence or new cancer, monitoring and treating complications and/or treatment side effects, and providing patient support.

Breast Cancer in Women: Diagnosis, Treatment and Follow-up

Year: 2013
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for female patients with breast cancer. The guideline examines management from diagnosis to treatment, with specific recommendations for multiple diagnoses and supportive treatments. Outcomes of interest include improved psychological outcomes with reduced time to breast reconstruction and improved progression free survival through treatment concurrent bevacizumab and chemotherapy.

Small Cell and Non-Small Cell Lung Cancer: Diagnosis, Treatment and Follow-up

Year: 2013
AGREE II score: Disponible
Developer organization: Belgian Health Care Knowledge Centre
A clinical practice guideline for patients with small cell and non-small cell lung cancer. The guideline examines lung cancer management from diagnosis to follow up, including considerations of tumour and organ risks. Outcomes of interest include increased treatment effectiveness through concurrent chemotherapy and improved post-operative management recommendations.

Multiple Myeloma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of multiple myeloma in adult patients. The guideline examines diagnosis and treatment for multiple myeloma, monoclonal gammopathy, smoldering myeloma, and amyloidosis, including prognostic criteria. Outcomes of interest include improved survival outcomes through triple drug based induction regimens and improved dose reduction options for elderly patients.

Upper Tract Urothelial Tumours

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for adult patients with upper tract urothelial carcinoma. The guideline examines staging, treatment, and follow-up, focusing on laboratory work-ups and primary therapy. Outcomes of interest include reduction of tumour recurrence through open bladder cuff excision and higher response rates with neoadjuvant chemotherapy.

Squamous Cell Carcinoma of the Vulva

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with squamous cell carcinoma of the vulva. The guideline reviews pre-operative investigations, primary treatment, adjuvant treatment, and follow-up and surveillance, with general and stage-specific recommendations provided. Outcomes of interest include cancer-related death rate, survival (overall and disease-free), progression-free interval, local control, and recurrence rate.

Evidence-Based Clinical Practice Guideline: Breast Reconstruction with Expanders and Implants

Year: 2013
AGREE II score: Disponible
Developer organization: American Society of Plastic Surgeons
A clinical practice guideline for patients who have undergone breast cancer treatment, mastectomy, and breast reconstruction. The guideline examines risk factors, optimal timing, and follow-up screening recommendations. Outcomes of interest include improved local control and antibiotic prophylaxis.

Follow-up for clinically localized renal neoplasms: AUA guideline

Year: 2013
AGREE II score: Unavailable
Developer organization: American Urological Association
A clinical practice guideline for the follow-up and surveillance of clinically localized renal cancers, not specifically including hereditary cancers. The guideline examines follow-up and continuing surveillance procedures based on prior treatment and patient history, specifically for surgical and ablative procedures. Outcomes of interest include effectiveness of screening tests, local and metastatic recurrence, metastatic progression, adverse events, and survival (overall and disease specific).

2013 Guidelines on Renal Cell Carcinoma

Year: 2013
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for the management of renal cell carcinoma. The guideline examines updates existing guidelines on diagnosis, staging, treatment, and follow-up, specifically focusing on improved data assessment. Outcomes of interest include improved evidence for the use of nephron-sparing surgery and increased use of surveillance for elderly patients.

Guidelines on muscle-invasive and metastatic bladder cancer

Year: 2013
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for muscle-invasive and metastatic bladder cancer patients. The guideline examines management stages including diagnosis, staging, treatment, and follow up. Outcomes of interest include optimised treatment options for elderly patients and improved survival outcomes with pre-surgical neoadjuvant radiotherapy.

Management of Epithelial Ovarian Cancer: A National Clinical Guideline

Year: 2013
AGREE II score: Disponible
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients diagnosed with or at risk of developing epithelial ovarian cancer. The guideline reviews risk factors and provides recommendations on screening, diagnosis, surgical management, chemotherapy, and follow-up care. Special topics of consideration include the role of prophylactic salpingo-oophorectomy in screening, and management of malignant bowel obstruction in relapsed disease. Outcomes of interest include diagnostic test accuracy, survival (overall and disease-free), response rates, quality of life, and adverse effects of treatment.

Follow-up and Surveillance of the Patient With Lung Cancer After Curative-Intent Therapy: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Year: 2013
AGREE II score: Disponible
Developer organization: American College of Chest Physicians
This is a clinical practice guideline for patients who have undergone treatment for primary lung cancer and are in follow-up. The guideline provides recommendations on post-treatment surveillance and follow-up procedures. CT scan, PET imaging, somatostatin receptor scintigraphy, abdominal ultrasonography, surveillance biomarker testing, and surveillance bronchoscopy are discussed as follow-up procedures. Other topics of discussion include the participation of the original treating physician in follow-up care, and the use of a validated health-related quality-of-life (QOL) instrument. Outcomes of interest include survival, quality of life and recurrence rate.

2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: European Thyroid Association
This is a clinical practice guideline for patients with metastatic medullary thyroid cancer. The guideline reviews diagnostic assessment, local treatment modalities, and systemic treatment (chemotherapy and clinical trials). It also discusses symptoms, evaluation, and treatment of hormonally active metastases. Outcomes of interest include survival, rate of progression, effectiveness of treatment, and toxicity.

Guidelines for Perioperative Care after Radical Cystectomy for Bladder Cancer: Enhanced Recovery After Surgery (ERAS) Society Recommendations

Year: 2013
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
A clinical practice guideline for patients with bladder cancer recovering from radical cystectomy. The guideline examines preoperative recommendations including medical optimization, intraoperative approaches, and perioperative management. Outcomes of interest include reduced complications and length of hospital stay.

Provincial Cervical Cancer Treatment Guidelines

Year: 2013
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with a positive diagnosis for cervical cancer. The guideline examines diagnosis and staging, and provides treatment recommendations based on cancer stage. Specific recommendations are also provided for pregnant patients. Outcomes of interest include improved use of adjuvant post-operative radiotherapy based on pathological findings.

Long-Term Management of the Successful Adult Liver Transplant: 2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

Year: 2013
AGREE II score: Unavailable
Developer organization: American Association for the Study of Liver Diseases
This clinical practice guideline reviews diagnostic, therapeutic, and preventive aspects of care for adult patients who have successfully undergone liver transplantation (LT). Topics include post-transplant monitoring and management of complications, as well as longer-term prevention and management of associated health conditions such as systemic and infectious diseases. Health promotion after LT is also discussed, with specific recommendations provided for bone health, nutrition and obesity, and reproductive health. Topics specific to oncology include screening for de novo cancer and management of recurrent or persistent cancer in LT patients.

Uterine Sarcoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for adult female patients with uterine sarcomas, including leiomyosarcoma, endometrial stromal sarcoma, and adenosarcoma. The guideline examines optimal surgical staging, adjuvant therapy, and palliative therapy. Outcomes of interest include improved progression-free survival rates and improved survival with the combination of gemcitabine and docetaxel.

Lymphoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients over 18 years of age with lymphoma. The guideline examines diagnostic assessment and staging procedures as well as treatment and management options. Follow-up and supportive care are also reviewed. Outcomes of interest include response rate (complete and overall), survival (progression-free and overall), time to disease progression, remission duration, freedom from treatment failure, impact of treatment on fertility, and toxicity from treatment.

Muscle Invasive and Locally Advanced/Metastatic Bladder Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients with muscle invasive bladder cancer (i.e., stages T2a/b, T3a/b, T4a and N0-X, M0). The guideline reviews evaluation and staging, treatment, and follow-up care according to stage. Outcomes of interest include survival, recurrence rate, bladder preservation rate, rate of metastasis, and presence of residual disease.

Referral and Follow-up Surveillance of Cutaneous Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for patients 18 years of age or older with malignant melanoma. Referral of patients to the cancer treatment centre is reviewed and follow-up and surveillance are discussed, with stage-specific recommendations provided. Outcomes of interest include quality of life, overall survival, regional control, time and expense of surveillance, and test sensitivity and false positive rates.

Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

Year: 2013
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for non-muscle-invasive bladder cancer patients. The guideline examines diagnosis and treatment, with specific reference to intravesical treatment techniques. Outcomes of interest include improved Bacillus Calmette-Guérin (BCG) immunotherapy protocols and improved early detection.

2013 Guidelines on Prostate Cancer

Year: 2013
AGREE II score: Disponible
Developer organization: European Association of Urology
A clinical practice guideline for the management of prostate cancer in adult males. The guideline examines the screening, diagnosis, treatment, and palliative options for prostate cancer patients, with reference to multiple options following failed curative intent treatments. Outcomes of interest include improved screening to rule out radical treatment and treatment deferral.

Management of Gastric Cancer in Asia: Resource-Stratified Guidelines

Year: 2013
AGREE II score: Unavailable
Developer organization: Asian Oncology Summit
A clinical practice guideline for patients with gastric cancers. The guideline examines diagnosis and management, including regional and resource-based recommendations. Outcomes of interest include increased HER2 testing and increased post-operative chemotherapy for palliative patients.

The Organization and Delivery of Healthcare Services for Head and Neck Cancer Patients

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical and organizational guideline for the management and delivery of services to head and neck cancer patients. The guideline examines delivery of care, healthcare qualifications, and infrastructure factors related to treatment and follow up. Important aspect include multidisciplinary team requirements including certifications and minimum patient volumes, and appropriate wait times for assessments and therapies.

The Committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma

Year: 2013
AGREE II score: Disponible
Developer organization: Japan Society of Hepatology
This is a clinical practice guideline for patients diagnosed with or at risk of developing hepatocellular carcinoma. The guideline reviews prevention, diagnosis and surveillance, surgery, percutaneous ablation therapy, transcatheter arterial chemoembolization (TACE), chemotherapy, and radiation therapy. Post-treatment surveillance, prevention of recurrence, and treatment of recurrent cancer are also reviewed. Outcomes of interest include survival, recurrence, disease progression, sensitivity, specificity, and predictive values of diagnostic tests, efficacy of surveillance and treatment techniques, surgical complications, and postoperative mortality.

Gestational Trophoblastic Disease: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Year: 2013
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for patients diagnosed with or suspected of having gestational trophoblastic disease (GTD). The guideline reviews diagnosis, staging, management of disease, and follow-up care. Treatment options for gestational trophoblastic tumours, placental site trophoblastic tumour/epithelioid trophoblastic tumours, and drug-resistant disease are reviewed. Outcomes of interest include survival, remission rate, toxicity, prognostic factors, and disease relapse.

Provincial Gestational Trophoblastic Neoplasia

Year: 2013
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for adult patients with gestational trophoblastic neoplasia including invasive mole, gestational choriocarcinoma, and placental site trophoblastic tumours. The guideline examines management, including concurrent diagnoses and chemotherapy recommendations. Outcomes of interest include reduced congenital malformations in future pregnancies, and improved response rates in maintenance chemotherapy.

Ovarian Germ Cell Tumours

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This clinical practice guideline reviews management/treatment of and follow-up care for women with ovarian germ cell tumours. Topics of interest include the efficacy of four cycles of etoposide and cisplatin as compared to the standard therapy with three cycles of bleomycin, etoposide, and cisplatin. Supportive care for myelosuppression is also discussed. Outcomes of interest include survival, mortality, relapse, time to progression, treatment response, and treatment complications and side effects.

Follow-up of Colorectal Polyps or Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: British Columbia Medical Association
This is a guideline for patients who have received curative resection of colorectal cancer (CRC) or polypectomy. The guideline provides recommendations on follow-up procedures and intervals depending on risk group. Follow-up visits are outlined and procedures including colonoscopy, imaging and x-rays, tumour markers, and fecal occult blood tests are reviewed. Long-term surveillance is also discussed.

Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

Year: 2013
AGREE II score: Disponible
Developer organization: American College of Chest Physicians
A clinical practice guideline for lung cancer patients who are potentially eligible for surgical resection. The guideline examines pre-operative assessment, primarily through lung function tests, to determine surgical risk. Recommendations are also made for treatment team qualifications and comparisons are made between available non-invasive function tests. Outcomes of interest include improved mortality with tobacco cessation and improved forced expiratory volume (FEV).

Fertility Preservation for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Year: 2013
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
This is a clinical practice guideline for adult and child patients with cancer. The guideline provides an overview of fertility preservation options for adult males, adult females, and children. Patient education and referral to reproductive specialists prior to cancer treatment are also discussed. Methods of fertility preservation are compared including cryopreservation options, hormonal therapy, and ovarian transposition (oophoropexy). Outcomes of interest include cost and effectiveness of preservation techniques, and effects of cancer treatments on fertility.

Primary Prophylaxis of Bacterial Infections and Pneumocystis Jirovecii Pneumonia in Patients With Hematological Malignancies and Solid Tumours

Year: 2013
AGREE II score: Unavailable
Developer organization: German Society of Hematology and Oncology (DGHO)
This is a clinical practice guideline for the use of antibacterial prophylaxis against bacteria and Pneumocystis pneumonia (PCP) in neutropenic cancer patients. This guideline examines the efficacy of different types of prophylaxis and offers guidance towards the choice of drug. Outcomes of interest include a reduction of severe infections, a delay of the onset of such infections to a later phase of neutropenia, avoidance of infection-related treatment delays, reduction of hospitalization, and reduction of treatment costs.

Follow-Up Care, Surveillance Protocol, and Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement

Year: 2013
AGREE II score: Unavailable
Developer organization: American Society of Clinical Oncology
A clinical practice guideline for survivors of colorectal cancer. The guideline examines appropriate follow-up and surveillance for stage II and III cancer survivors, including appropriate timing, supportive care, and secondary prevention. Outcomes of interest include improved prevention through lifestyle changes and increasing carcinoembryonic antigen testing when necessary.

International Clinical Practice Guidelines for the Treatment and Prophylaxis of Venous Thromboembolism in Patients With Cancer

Year: 2013
AGREE II score: Disponible
Developer organization: International Society on Thrombosis and Haemostasis
A clinical practice guideline for cancer patients at risk for venous thromboembolism. The guideline examines prophylactic treatment through anticoagulant therapy, specifically short-term unfractionated heparin and low-molecular-weight heparin. Outcomes of interest include preference for low-molecular-weight heparin for primary treatment, and improved maintenance treatments.

Guidelines for the Management of Malignant Melanoma

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
A clinical practice guideline for patients with malignant melanoma. The guideline examines management from diagnosis to follow-up, including referral processes, recommendations for pregnant patients, and supportive care. Outcomes of interest include improved recommendations for the timing and efficacy of sentinel lymph node biopsy, which is generally recommended as a first-line staging tool.

Optimal Treatment Options and Follow-up Strategies in Patients with Desmoid Tumours

Year: 2013
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
A clinical practice guideline for patients with desmoid tumours who are either pursuing active treatment or have already received primary treatment. The guideline examines treatment and follow-up strategies, including recommendations for multiple concurrent treatment options and appropriate rehabilitation. Outcomes of interest include lack of statistically significant information for optimal treatment choice, and increased focus on multidisciplinary sarcoma teams.

Management of Squamous Cell Cancer of the Anal Canal

Year: 2013
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adult patients with a primary diagnosis of biopsy-proven squamous cell cancer of the anal canal, including basaloid, cloacogenic, and transitional cell tumours. The guideline reviews treatment and follow-up care for squamous cell cancer, with radiotherapy and chemotherapy discussed as treatment options. Outcomes of interest include colostomy rate, local failure, survival, adverse effects (acute and late), and quality of life.

Cancer of the Uterine Cervix

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for adult patients with cancer of the uterine cervix, including squamous, adenocarcinomas, and adenosquamous carcinomas. The guideline reviews evaluation and staging, treatment, and follow-up procedures. Management of recurrent disease is also discussed. Outcomes of interest include survival (overall, disease-free, and progression-free), overall response rate, and toxicity.

Prostate Cancer

Year: 2013
AGREE II score: Unavailable
Developer organization: Alberta Health Services
This is a clinical practice guideline for men with prostate cancer or suspected prostate cancer. The guideline provides an overview of early diagnostic and screening procedures, management and treatment options, and follow-up care for low-risk, intermediate-risk, and advanced disease. The guideline also reviews bone health and the use of bisphosphonates as treatment for castrate resistant disease. Outcomes of interest include mortality, quality of life, morbidity, treatment complications, and toxicity.

Renal Cell Carcinoma

Year: 2012
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for the management of patients with renal cell carcinoma. The guideline examines diagnostic assessment and appropriate first and second line therapies, including surgical and minimally invasive therapies. Outcomes of interest include increased assessment for treatment tolerance, and improved median survival.

The Dutch Childhood Oncology Group Guideline for Follow-Up of Asymptomatic Cardiac Dysfunction in Childhood Cancer Survivors

Year: 2012
AGREE II score: Disponible
Developer organization: Dutch Childhood Oncology Group
This is a clinical practice guideline for childhood cancer survivors (CCS). The guideline reviews the risk of cardiac dysfunction in CCS and provides recommendations on screening technique and intervals for asymptomatic patients and follow-up care for abnormal results. The guideline also discusses counselling strategies to inform patients of individual estimated risk and the potential advantages and disadvantages of screening. Outcomes of interest include all-cause mortality, cardiovascular mortality, development of clinical heart failure and development of congestive heart failure in CCS.

Breast Cancer Treatment Guidelines

Year: 2012
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for the screening and treatment of primary, locally recurrent, and metastatic breast cancer. The guideline identifies individuals requiring screening, and offers treatment and follow up options for multiple procedures and therapies. Outcomes of interest include reduced mortality and eliminating unnecessary lab work.

Ependymomas

Year: 2012
AGREE II score: Disponible
Developer organization: Alberta Health Services
A clinical practice guideline for patients over the age of 18 with WHO grades II or III anaplastic ependymomas. The guideline provides recommendations on treatment and follow-up. Specific techniques include surgery, postoperative MRI, radiotherapy, and chemotherapy. The primary outcome of interest is survival rate.

ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial Carcinoma of the Prostate

Year: 2012
AGREE II score: Unavailable
Developer organization: European Association of Urology
This is a clinical practice guideline for urothelial carcinoma (UC) of the prostate. This guideline provides diagnosis, treatment, and follow-up recommendations. Areas of interest include treatment with intravesical bacillus Calmetter-Guerin (BCG), transurethral biopsy of the prostatic urethra, as well as radical cystoprostatectomy.

Thymic Neoplasms

Year: 2012
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with thymic neoplasms. The guideline examines staging based treatment and follow up, focusing on surgical resection and postoperative radiotherapy. Outcomes of interest include reduced relapse and improved multimodal treatment regimens.

Melanoma Guideline 2012

Year: 2012
AGREE II score: Unavailable
Developer organization: Integraal Kankercentrum Nederland
A clinical practice guideline for patients with melanoma of the skin. The guideline examines management and daily practice support for melanoma, including genetic risk-based screening, and appropriate excision. Outcomes of interest include reduced recurrence through larger excision margins and improved prevention recommendations.

Provincial Hodgkin’s Lymphoma Treatment Guidelines

Year: 2012
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
This is a clinical practice guideline for Hodgkin's lymphoma patients in Saskatchewan. The guideline provides an overview of procedures related to diagnosis, staging, treatment, relapse treatment, and follow-up for Hodgkin's lymphoma. The guideline considers both remission and palliative treatment outcomes.

Provincial Melanoma Treatment Guidelines

Year: 2012
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline for patients with suspected or confirmed melanoma. The guideline examines management, including pathology, and imaging and treatment recommendations based on staging. Outcomes of interest include special considerations for Braff mutations and reduced unnecessary follow up testing.

Bone Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This clinical practice guideline is for cancer patients who are being considered for anti-TNF-alpha therapy. Treatment related infections are reviewed, including tuberculosis, human papilloma virus, hepatitis B and C, Varicella zoster virus, Herpes simplex virus, cytomegalovirus, Epstein Barr virus and human immunodeficiency virus. The guideline discusses risk factors for developing infection, and provides recommendations on preventative measures such as vaccination for at-risk individuals.

Stage I NSGCT Surveillance Recommendations

Year: 2012
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
A clinical practice guideline for patients with Stage I nonseminomatous germ cell tumours. The guideline examines baseline staging procedures and subsequent follow-up post orchiectomy. The guideline also provides monthly follow-up screening recommendations based on risk associated with lymphovascular invasion.

Follow Up Guidelines for Patients Who Have Undergone Curative Surgery for Renal Cell Carcinoma

Year: 2012
AGREE II score: Unavailable
Developer organization: Cancer Care Nova Scotia
A clinical practice guideline detailing follow-up procedures for patients who have undergone curative renal cell carcinoma surgery. The guideline provides timelines for follow-up based on ECOG performance status, and gives detailed information for physicians about the importance of pathology results, and the surgical procedures conducted.

Lymphoma

Year: 2012
AGREE II score: Disponible
Developer organization: Alberta Health Services
This is a clinical practice guideline on the diagnosis, staging, treatment, supportive interventions and follow-up care for adult patients with lymphoma. Staging techniques include immunohistochemical and fluorescence in situ hybridization (FISH) testing. Treatment and management options are discussed for Hodgkin and non-Hodgkin lymphomas, with recommendations based on cancer type and stage. Outcomes of interest include response rates, disease progression, survival, remission, and adverse effects.

Gestational Trophoblastic Neoplasia

Year: 2012
AGREE II score: Disponible
Developer organization: Alberta Health Services
This is a clinical practice guideline for women with gestational trophoblastic neoplasia, including invasive mole, choriocarcinoma, and placental site trophoblastic tumour. The guideline provides recommendations on diagnostic assessment, staging, prognostic scoring, treatment, and follow-up procedures. Outcomes of interest include diagnostic accuracy, complete response rate, survival rate, and risk of subsequent abnormal pregnancy.

Bone Health in Patients with Breast Cancer

Year: 2012
AGREE II score: Disponible
Developer organization: Alberta Health Services
A clinical practice guideline for breast cancer patients with bone metastases or at risk for induced bone loss. The guideline examines the use of bone-modifying agents and their administration with special considerations given to contraindicated medications and additional risk factors. Outcomes of interest include treatment efficacy, recurrence, and survival.

Bone Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for the management of bone sarcomas including osteosarcoma, Ewing sarcoma, high-grade spindle/pleomorphic sarcomas of bone, chondrosarcoma, giant cell tumour of bone, and chordoma. The guideline provides recommendations on diagnostic assessment and staging, treatment, and follow-up care. Outcomes of interest include incidence of subtypes, local recurrence, and survival.

Soft Tissue and Visceral Sarcomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
A clinical practice guideline for the management of patients with soft tissue and visceral sarcomas. The guideline examines surgical intervention with systemic therapies, following diagnosis and staging through imaging and core needle biopsies. Considerations include risk of relapse and differences in treatment for special presentations.

Models of Care for Cancer Survivorship

Year: 2012
AGREE II score: Disponible
Developer organization: Cancer Care Ontario
This is a clinical practice guideline for adults without evidence of disease after primary, curative treatment for any stage of cancer. The guideline reviews models of care for cancer survivorship and looks at whether certain models are favoured for specific cancer types. Outcomes of interest include disease-free survival, mortality (cancer-related and all cause), morbidity (late effects), time to recurrence, quality of life, and patient satisfaction.

Breast Cancer Follow-up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update

Year: 2012
AGREE II score: Disponible
Developer organization: American Society of Clinical Oncology
A clinical practice guideline for breast cancer patients who have completed primary curative therapy. The guideline examines management and follow-up of breast cancer screening and provides recommendations for testing options and monitoring frequency. Coordination of care, breast imaging comparisons, and patient self-examination counseling are also discussed. Outcomes of interest include survival (overall and disease-free), quality of life, toxicity reduction and cost effectiveness.

The Organization and Delivery of Healthcare Services for Head and Neck Cancer Patients

Year: 2012
AGREE II score: Disponible
Developer organization: Alberta Health Services
This is a professional guideline that provides recommendations on the organization and delivery of health-care services for head and neck cancer patients in Alberta. The guideline outlines the professional health-care team involved in the treatment of head and neck cancer patients, including their roles and minimum required qualifications. It also provides guidance on minimum infrastructure requirements, optimal cancer centre and team member volumes, and wait times to care from referral to initiation of curative treatment.

Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up

Year: 2012
AGREE II score: Unavailable
Developer organization: European Society for Medical Oncology
This is a clinical practice guideline for head and neck cancer patients (HNCPs) undergoing radiotherapy. The guideline reviews dysphagia mechanisms and causes in HNCPs and provides recommendations on the management of patients undergoing radiotherapy who have pre-treatment dysphagia or are at risk for dysphagia. The occurrence of dysphagia in post-surgical radiotherapy or after chemoradiotherapy is also discussed.

Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS) Society Recommendations

Year: 2012
AGREE II score: Unavailable
Developer organization: Enhanced Recovery After Surgery Group
This clinical practice guideline discusses pre- and peri-operative care interventions for patients undergoing elective rectal or pelvic surgery. Comparisons are made between rectal resection and colon resection recommendations, specifically in pre-operative counselling and optimisation. Outcomes of interest include rates of anastamotic leaks, length of hospital stay, and post-operative morbidity.

Follow-Up Guidelines Central Nervous System

Year: 2012
AGREE II score: Unavailable
Developer organization: Saskatchewan Cancer Agency
A clinical practice guideline follow-up to the Provincial Central Nervous System Cancer Treatment Guidelines produced by the Saskatchewan Cancer Agency in 2011. The guideline provides updated follow-up recommendations for patients with anaplastic gliomas, glioblastomas, or low grade gliomas.

Management of Chronic Myeloid Leukemia

Year: 2012
AGREE II score: Disponible
Developer organization: Alberta Health Services
This is a clinical practice guideline on the management of chronic myeloid leukemia in patients over 18 years of age. The guideline provides recommendations on staging and prognosis, diagnosis and baseline investigations, treatment options, and treatment response assessment. First and second generation TKI's, induction chemotherapy, allogeneic stem cell transplant, and interferon-a are all discussed as treatment options. Outcomes of interest include treatment efficacy, survival rate, disease progression, and adverse events.

Non-Small Cell Lung Cancer Stage II

Year: 2011
AGREE II score: Unavailable
Developer organization: Alberta Health Services
A clinical practice guideline for patients with stage II non-small cell lung cancer. The guideline examines diagnostic workup, treatment, and follow up for operable and inoperable patients. Outcomes of interest include improved early detection of recurrence and reduced complications through video-assisted thoracic surgery.

Guidelines on the Investigation and Management of Follicular Lymphoma

Year: 2011
AGREE II score: Unavailable
Developer organization: British Committee for Standards in Haematology
This is a clinical practice guideline on the diagnosis and laboratory investigation, treatment management, follow-up and monitoring of patients with follicular lymphoma (FL). Topics of interest include the use of prognostic scoring systems and the role of autologous and allogeneic transplant in the treatment of FL. Outcomes of interest include survival (overall, event-free and progression free), relapse risk, transplant-related mortality and overall response rate to treatment.

Guidelines for the Management of Gastroenteropancreatic Neuroendocrine (Including Carcinoid) Tumours (NETs)

Year: 2011
AGREE II score: Unavailable
Developer organization: UK and Ireland Neuroendocrine Tumour Society
This is a clinical practice guideline for patients with gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Genetic risk factors, diagnostic assessment including imaging and pathology, and treatment are discussed. Special topics of interest include genetic risk factors and association of NETs with carcinoid heart disease (CHD). Outcomes of interest include survival rates, sensitivity of diagnostic testing procedures, adverse effects and quality of life.

Indications for Use of Breast Magnetic Resonance Imaging (MRI)

Year: 2011
AGREE II score: Unavailable
Developer organization: Eastern Health
A clinical practice guideline for the use of MRI in breast cancer screening for patients who have hereditary risk, or have had previous radiation. The guideline examines indications and contraindications for breast MRI in screening, assessment, evaluation of treatment, and follow up. Outcomes of interest include MRI sensitivity and specificity.

Cancer Rehabilitation

Year: 2011
AGREE II score: Disponible
Developer organization: Dutch Association of Comprehensive Cancer Centres
This clinical practice guideline examines cancer rehabilitation and is aimed at patients over 18 years of age who are undergoing or have completed cancer treatment. The guideline reviews long-term and late effects of general cancer treatment and provides recommendations on screening for adverse effects, referral and intake, and rehabilitation programs during curative treatment, after completion of curative treatment, and in the palliative phase. Work reintegration and social participation is also reviewed.

Basal Cell Carcinoma, Squamous Cell Carcinoma (And Related Lesions) – A Guide to Clinical Management in Australia

Year: 2008
AGREE II score: Unavailable
Developer organization: Cancer Council Australia
A clinical practice guideline for patients with basal cell carcinoma, squamous cell carcinoma, and other keratinocyte tumours. The guideline examines multiple treatment options such as surgery, radiotherapy, cryotherapy and photodynamic therapy based on clinical presentation and prognosis. Outcomes of interest include primary prevention and improved lesion assessment.

Oncology Nursing Documentation Competencies

Year: 2008
AGREE II score: Unavailable
Developer organization: Cancer Care Ontario
A professional guideline for oncology nursing competencies. The guideline examines guiding principles for nurses throughout the cancer continuum, and enumerates core competencies. Important aspects include both clinical and supportive competencies, and a focus on accountability and quality improvement.